CITATION REPORT List of articles citing

Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research

DOI: 10.1002/jbmr.1998 Journal of Bone and Mineral Research, 2014, 29, 1-23.

Source: https://exaly.com/paper-pdf/58677264/citation-report.pdf

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper IF	Citations
1072	Clinical update on nursing home medicine: 2013. 2013 , 14, 860-76	9
1071	Prevention and treatment of bone changes associated with exposure to glucocorticoids. 2013, 11, 341-7	11
1070	Atypical femoral fractures. 2013 , 18, 125-127	1
1069	Incomplete atypical femoral fractures: assessing the diagnostic utility of DXA by extending femur length. 2013 , 16, 579-83	36
1068	Bone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian Guideline. 2013 , 2, 283-301	7
1067	Atypical femoral fracture combined with osteonecrosis of jaw during osteoporosis treatment with bisphosphonate. 2014 , 21, 155-9	11
1066	Physicians' attitudes to contemporary issues on osteoporosis management in Korea. 2014 , 21, 143-9	19
1065	Atypical femoral fracture in an osteogenesis imperfecta patient successfully treated with teriparatide. 2014 , 20, e187-90	18
1064	Surgical Treatment in Atypical Diaphyseal Femoral Fracture with Anterior and Lateral Bowing. 2014 , 49, 485	7
1063	Commentary: drug-associated atypical femoral fractures (DaAFFs): balancing the facts. 2014 , 99, 2340-2	4
1062	Atypical femur fractures: a review. 2014 , 12, 446-53	15
1061	Identifying atypical femoral fracturesa retrospective review. 2014 , 95, 405-12	8
1060	Histology of 8 atypical femoral fractures: remodeling but no healing. 2014 , 85, 280-6	57
1059	Bisphosphonate-associated atypical femoral fractures and one-year mortality. 2014 , 119, 357-8	5
1058	Atypical femoral fractures bilaterally in a patient receiving denosumab. 2014 , 85, 3-5	42
1057	Re: absence of femoral cortical thickening in long-term bisphosphonate users: Implications for atypical femur fractures. 2014 , 68, 165	
1056	Association of atypical femoral fractures with bisphosphonate use by patients with varus hip geometry. 2014 , 96, 1905-9	59

1055	Osteoporosis and fracture risk associated with HIV infection and treatment. 2014 , 43, 769-80	19
1054	Research perspectives: The 2013 AAOS/ORS research symposium on Bone Quality and Fracture Prevention. 2014 , 32, 855-64	11
1053	Bisphosphonate-Associated Atypical Femur Fracture. 2014 , 44, 35-37	2
1052	Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy. 2014 , 20, 3955-61	27
1051	Osteoporosis epidemiology 2013: implications for diagnosis, risk assessment, and treatment. 2014 , 26, 440-6	63
1050	Osteoporosis presenting in pregnancy, puerperium, and lactation. 2014 , 21, 468-75	26
1049	Established and forthcoming drugs for the treatment of osteoporosis. 2014 , 26, 245-51	12
1048	2014 Female Athlete Triad Coalition consensus statement on treatment and return to play of the female athlete triad: 1st International Conference held in San Francisco, CA, May 2012, and 2nd International Conference held in Indianapolis, IN, May 2013. 2014 , 24, 96-119	97
1047	Atypical femoral fractures in elderly women: a fracture registry-based cohort study. 2014 , 96-B, 1035-40	22
1046	Symptomatic atypical femoral fractures are related to underlying hip geometry. 2014 , 63, 1-6	63
1045	Femur fracture classification in women with a history of breast cancer. 2014 , 3, 49-53	6
1044	Theoretical consideration of the effect of drug holidays on BMD and tissue age. 2014 , 25, 1577-84	3
1043	Review: epidemiology and pathophysiology of atypical femur fractures. 2014 , 12, 65-73	8
1042	CORR Insights : Are race and sex assessment associated with the occurrence of atypical femoral fractures?. 2014 , 472, 1028-9	
1041	The clinical characteristics of patients with hip fractures in typical locations and atypical femoral fractures. 2014 , 9, 171	6
1040	Weekly Teriparatide for Delayed Unions of Atypical Subtrochanteric Femur Fractures. 2014 , 4, 73-9	23
1039	Atypical femoral fractures after anti-osteoporotic medication: a Korean multicenter study. 2014 , 38, 1247-53	37
1038	Modelling the cost effectiveness of interventions for osteoporosis: issues to consider. 2014 , 32, 735-43	8

1037	Effect of TNF-alpha inhibitor treatment on bone mineral density in patients with ankylosing spondylitis: a systematic review and meta-analysis. 2014 , 44, 155-61	46
1036	Status of drug development for the prevention and treatment of osteoporosis. 2014 , 9, 245-53	16
1035	Imaging of Osteoporotic Fractures on XR, CT, and MR. 2014 , 2, 1	6
1034	Femoral shaft strains during daily activities: Implications for atypical femoral fractures. 2014 , 29, 869-76	60
1033	Clinician's Guide to Prevention and Treatment of Osteoporosis. 2014 , 25, 2359-81	1775
1032	Risk of atypical femoral fractures and osteonecrosis of the jaw associated with alendronate use compared with other oral bisphosphonates. 2014 , 53, 1911-3	12
1031	Potential pathogenic mechanism for stress fractures of the bowed femoral shaft in the elderly: Mechanical analysis by the CT-based finite element method. <i>Injury</i> , 2014 , 45, 1764-71	47
1030	Efficacy and safety of currently marketed anti-osteoporosis medications. 2014 , 28, 809-34	33
1029	The fracture sites of atypical femoral fractures are associated with the weight-bearing lower limb alignment. 2014 , 66, 105-10	57
1028	Development, validation and characterization of a novel mouse model of Adynamic Bone Disease (ABD). 2014 , 68, 57-66	8
1027	Post-operative outcomes of atypical femoral subtrochanteric fracture in patients on bisphosphonate therapy. 2014 , 96-B, 658-64	73
1026	Gender related difference in the risk of bisphosphonate associated atypical femoral fracture and osteonecrosis of the jaw. 2014 , 73, 1594	11
1025	The correlation between lateral bowing angle of the femur and the location of atypical femur fractures. 2014 , 95, 240-7	39
1024	External auditory canal and middle ear cholesteatoma and osteonecrosis in bisphosphonate-treated osteoporosis patients: a Danish national register-based cohort study and literature review. 2014 , 25, 1937-44	18
1023	Tibial bone versican content decreases with zoledronate treatment in adult mice. 2014 , 25, 1975-81	2
1022	Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries. 2014 , 25, 2109-16	33
1021	Stress fracture of the ulna associated with bisphosphonate therapy and use of walking aid. 2014 , 25, 2151-4	11
1020	Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update. 2014 , 32, 337-50	92

1019	Stress fracture of the bowed femoral shaft is another cause of atypical femoral fracture in elderly Japanese: a case series. 2014 , 19, 579-86		50
1018	Atypical femoral fractures in association with bisphosphonate therapy: a case series. 2014 , 21, 557-62		8
1017	Atypical femoral fractures, bisphosphonates, and mechanical stress. 2014 , 12, 189-93		24
1016	Changes in the degree of mineralization with osteoporosis and its treatment. 2014 , 12, 338-50		42
1015	Risk of atypical femoral fracture during and after bisphosphonate use. <i>New England Journal of Medicine</i> , 2014 , 371, 974-6	59.2	113
1014	Osteoporosis and multiple sclerosis: risk factors, pathophysiology, and therapeutic interventions. 2014 , 28, 731-42		27
1013	Bone disease in CKD: a focus on osteoporosis diagnosis and management. 2014 , 64, 290-304		77
1012	Bilateral atypical femoral fractures in a patient prescribed denosumab - a case report. 2014 , 61, 44-7		58
1011	Absence of femoral cortical thickening in long-term bisphosphonate users: implications for atypical femur fractures. 2014 , 62, 64-6		23
1010	Insights into reference point indentation involving human cortical bone: sensitivity to tissue anisotropy and mechanical behavior. 2014 , 37, 174-85		46
1009	Atypical femur fractures. 2014 , 30, 349-59		10
1008	Chronic kidney disease and the skeleton. 2014 , 2, 14044		28
1007	Postsurgical hypoparathyroidismrisk of fractures, psychiatric diseases, cancer, cataract, and infections. <i>Journal of Bone and Mineral Research</i> , 2014 , 29, 2504-10	6.3	137
1006	Osteoporotic Fracture Care: Are We Closer to Gold Standards?. 2015 , 29 Suppl 12, S53-6		9
1005	Atypical femoral fracture in osteoporosis pseudoglioma syndrome associated with two novel compound heterozygous mutations in LRP5. <i>Journal of Bone and Mineral Research</i> , 2015 , 30, 615-20	6.3	22
1004	True Gold or Pyrite: A Review of Reference Point Indentation for Assessing Bone Mechanical Properties In Vivo. <i>Journal of Bone and Mineral Research</i> , 2015 , 30, 1539-50	6.3	63
1003	PTH(1-34) Treatment Increases Bisphosphonate Turnover in Fracture Repair in Rats. <i>Journal of Bone and Mineral Research</i> , 2015 , 30, 1022-9	6.3	18
1002	Trends in Media Reports, Oral Bisphosphonate Prescriptions, and Hip Fractures 1996-2012: An Ecological Analysis. <i>Journal of Bone and Mineral Research</i> , 2015 , 30, 2179-87	6.3	143

1001	Osteoporosis: the emperor has no clothes. 2015 , 277, 662-73		37
1000	Atypical Vancouver Type-C Periprosthetic Fracture Complicated by Nonunion: A Case Report. 2015 , 5, e44		9
999	Bilateral Atypical Femoral Fracture in a Man on Long-Term Bisphosphonate and Glucocorticoid Therapy: A Case Report. 2015 , 5, e36		2
998	Obliteration of the medullary canal in an atypical bisphosphonate-related femoral fracture. 2015 , 2015,		
997	Use of anti-osteoporotic drugs in central Norway after a forearm fracture. 2015 , 10, 235		10
996	Atypical Fractures are Mainly Subtrochanteric in Singapore and Diaphyseal in Sweden: A Cross-Sectional Study. <i>Journal of Bone and Mineral Research</i> , 2015 , 30, 2127-32	6.3	29
995	Baseline age and time to major fracture in younger postmenopausal women. 2015 , 22, 589-97		14
994	Subtrochanteric femur fractures: review of the complete pathologic spectrum with emphasis on distinguishing imaging features. 2015 , 39, 47-56		2
993	Evaluation of a Nationwide Pharmacist-Led Phone Outreach Program to Improve Osteoporosis Management in Older Women with Recently Sustained Fractures. 2015 , 21, 803-10		5
992	Periprosthetic Atypical Femoral Fracture-like Fracture after Hip Arthroplasty: A Report of Three Cases. 2015 , 27, 187-91		12
991	Atypical Femoral Fracture: 2015 Position Statement of the Korean Society for Bone and Mineral Research. 2015 , 22, 87-91		13
990	Pathogenesis, management and prevention of atypical femoral fractures. 2015 , 22, 1-8		16
989	Position Statement: Drug Holiday in Osteoporosis Treatment with Bisphosphonates in South Korea. 2015 , 22, 167-74		15
988	Effect of Teriparatide on Healing of Atypical Femoral Fractures: A Systemic Review. 2015 , 22, 183-9		50
987	Delayed healing of lower limb fractures with bisphosphonate therapy. 2015 , 97, 333-8		21
986	Combined Effect of a Locking Plate and Teriparatide for Incomplete Atypical Femoral Fracture: Two Case Reports of Curved Femurs. 2015 , 2015, 213614		10
985	Does the Time of Postoperative Bisphosphonate Administration Affect the Bone Union in Osteoporotic Intertrochanteric Fracture of Femur?. 2015 , 27, 258-64		4
984	Nonsurgical Treatment Strategies after Osteoporotic Hip Fractures. 2015 , 27, 9-16		2

(2015-2015)

983	Pharmacological diversity among drugs that inhibit bone resorption. 2015 , 22, 115-30		24
982	Fatigue-induced microdamage in cancellous bone occurs distant from resorption cavities and trabecular surfaces. 2015 , 79, 8-14		17
981	Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. 2015 , 386, 433-43		357
980	[Imaging of diabetic osteopathy]. 2015 , 55, 329-36		O
979	Bone Material Properties and Skeletal Fragility. 2015 , 97, 213-28		19
978	Atypical femoral fracture in a patient treated with denosumab. 2015 , 33, 355-8		39
977	Healing of bisphosphonate-associated atypical femoral fractures in patients with osteoporosis: a comparison between treatment with and without teriparatide. 2015 , 33, 553-9		74
976	Rare non-traumatic periprosthetic femoral fracture with features of an atypical femoral fracture: a case report. 2015 , 9, 103		24
975	Atypical femoral fractures and bisphosphonate use: current evidence and clinical implications. 2015 , 6, 185-93		46
974	Association between alendronate and atypical femur fractures: a meta-analysis. 2015, 4, 58-64		10
973	High revision rate but good healing capacity of atypical femoral fractures. A comparison with common shaft fractures. <i>Injury</i> , 2015 , 46, 2468-73	2.5	36
972	Recent advances in the pathogenesis and treatment of osteoporosis. 2015 , 15 Suppl 6, s92-6		30
971	The smallest available estradiol transdermal patch: a new treatment option for the prevention of postmenopausal osteoporosis. 2015 , 11, 815-24		7
970	A rare case of bilateral proximal femoral insufficiency fractures after interlocking IM nailing for bilateral atypical femoral shaft fractures. 2015 , 135, 1227-32		8
969	Emerging therapeutic concepts for muscle and bone preservation/building. 2015, 80, 150-156		8
968	Mtastases osseuses des cancers bronchopulmonaires. 2015 , 7, 445-454		
967	Recognition of the Causative Agent of Phossy Jawland Bragile Femurlin Fumes Arising from White Phosphorus. 2015 , 190, 2082-2093		4
966	SECOT-GEIOS guidelines in osteoporosis and fragility fracture. An update. 2015 , 59, 373-393		

965	The skeletal muscle cross sectional area in long-term bisphosphonate users is smaller than that of bone mineral density-matched controls with increased serum pentosidine concentrations. 2015 , 75, 84-7	19
964	The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). <i>Journal of Bone and Mineral Research</i> , 2015 , 6.3 30, 934-44	152
963	[Atypical femoral fracture in patient with over 12 years of unsupervised bisphosphonate therapy]. 2015 , 50, 46-7	1
962	The Effect of Osteoporosis Treatments on Fatigue Properties of Cortical Bone Tissue. 2015 , 2, 8-13	20
961	Atypical Femoral Fractures: A Teaching Perspective. 2015 , 66, 102-7	12
960	Long-term safety of antiresorptive treatment: bone material, matrix and mineralization aspects. 2015 , 4, 634	9
959	Dramatic osteonecrosis of the jaw associated with oral bisphosphonates, periodontitis, and dental implant removal. 2015 , 42, 190-5	16
958	Questioning the association between bisphosphonates and atypical femoral fractures. 2015 , 1335, 1-9	9
957	Management of osteoporosis in rheumatoid arthritis patients. 2015 , 16, 559-71	48
956	Risk of atypical femoral fracture during and after bisphosphonate use. 2015 , 86, 100-7	106
956 955	Risk of atypical femoral fracture during and after bisphosphonate use. 2015 , 86, 100-7 Bisphosphonate-associated atypical sub-trochanteric femur fractures: paired bone biopsy quantitative histomorphometry before and after teriparatide administration. 2015 , 44, 477-482	106
	Bisphosphonate-associated atypical sub-trochanteric femur fractures: paired bone biopsy	
955	Bisphosphonate-associated atypical sub-trochanteric femur fractures: paired bone biopsy quantitative histomorphometry before and after teriparatide administration. 2015 , 44, 477-482 Multi-level characterization of human femoral cortices and their underlying osteocyte network	26
955 954	Bisphosphonate-associated atypical sub-trochanteric femur fractures: paired bone biopsy quantitative histomorphometry before and after teriparatide administration. 2015 , 44, 477-482 Multi-level characterization of human femoral cortices and their underlying osteocyte network reveal trends in quality of young, aged, osteoporotic and antiresorptive-treated bone. 2015 , 45, 46-55	26
955 954 953	Bisphosphonate-associated atypical sub-trochanteric femur fractures: paired bone biopsy quantitative histomorphometry before and after teriparatide administration. 2015, 44, 477-482 Multi-level characterization of human femoral cortices and their underlying osteocyte network reveal trends in quality of young, aged, osteoporotic and antiresorptive-treated bone. 2015, 45, 46-55 Treatment of osteoporosis: current state of the art. 2015, 165, 54-64 A grape-enriched diet increases bone calcium retention and cortical bone properties in	26 64 8
955 954 953 952	Bisphosphonate-associated atypical sub-trochanteric femur fractures: paired bone biopsy quantitative histomorphometry before and after teriparatide administration. 2015, 44, 477-482 Multi-level characterization of human femoral cortices and their underlying osteocyte network reveal trends in quality of young, aged, osteoporotic and antiresorptive-treated bone. 2015, 45, 46-55 Treatment of osteoporosis: current state of the art. 2015, 165, 54-64 A grape-enriched diet increases bone calcium retention and cortical bone properties in ovariectomized rats. 2015, 145, 253-9 Ulnar fractures with bisphosphonate therapy: a systematic review of published case reports. 2015,	26 64 8
955 954 953 952 951	Bisphosphonate-associated atypical sub-trochanteric femur fractures: paired bone biopsy quantitative histomorphometry before and after teriparatide administration. 2015, 44, 477-482 Multi-level characterization of human femoral cortices and their underlying osteocyte network reveal trends in quality of young, aged, osteoporotic and antiresorptive-treated bone. 2015, 45, 46-55 Treatment of osteoporosis: current state of the art. 2015, 165, 54-64 A grape-enriched diet increases bone calcium retention and cortical bone properties in ovariectomized rats. 2015, 145, 253-9 Ulnar fractures with bisphosphonate therapy: a systematic review of published case reports. 2015, 26, 421-9	26 64 8 18

(2015-2015)

947	[SECOT-GEIOS guidelines in osteoporosis and fragility fracture. An update]. 2015, 59, 373-93	14
946	Tibial stress reaction presenting as bilateral shin pain in a man taking denosumab for giant cell tumor of the bone. 2015 , 81, 31-35	4
945	Prolonged risk of subtrochanteric and diaphyseal femur fractures after discontinuing alendronate treatment: A nationwide nested case-control study in Taiwan. 2015 , 6, 54-58	
944	Bone cross-sectional geometry is not associated with atypical femoral fractures in Asian female chronic bisphosphonate users. 2015 , 79, 170-5	11
943	Fracture atypique chez un enfant atteint dune ostògenße imparfaite. 2015 , 82, 267-268	
942	Bisphosphonates and glucocorticoid-induced osteoporosis: cons. 2015 , 49, 628-34	15
941	Atypical femur fractures associated with use of bisphosphonates and denosumab. 2015 , 26, 819-820	8
940	Atypical Fractures of the Femur: Evaluation and Treatment. 2015 , 3,	7
939	Bisphosphonate-associated peri-implant fractures: a new clinical entity? A series of 10 patients with 11 fractures. 2015 , 86, 622-6	20
938	The Pathophysiology and Treatment of Osteoporosis. 2015 , 37, 1837-50	149
938	The Pathophysiology and Treatment of Osteoporosis. 2015, 37, 1837-50 Atypical Subtrochanteric Femoral Fracture Below an Arthritic Hip: A Case Report. 2015, 5, e1	149
937	Atypical Subtrochanteric Femoral Fracture Below an Arthritic Hip: A Case Report. 2015 , 5, e1 American Society of Biomechanics Journal of Biomechanics Award 2013: cortical bone tissue	1
937	Atypical Subtrochanteric Femoral Fracture Below an Arthritic Hip: A Case Report. 2015, 5, e1 American Society of Biomechanics Journal of Biomechanics Award 2013: cortical bone tissue mechanical quality and biological mechanisms possibly underlying atypical fractures. 2015, 48, 883-94	1 20
937 936 935	Atypical Subtrochanteric Femoral Fracture Below an Arthritic Hip: A Case Report. 2015, 5, e1 American Society of Biomechanics Journal of Biomechanics Award 2013: cortical bone tissue mechanical quality and biological mechanisms possibly underlying atypical fractures. 2015, 48, 883-94 Bisphosphonates and Atypical Femoral Fractures. 2015, 11, 389-396	1 20
937 936 935 934	Atypical Subtrochanteric Femoral Fracture Below an Arthritic Hip: A Case Report. 2015, 5, e1 American Society of Biomechanics Journal of Biomechanics Award 2013: cortical bone tissue mechanical quality and biological mechanisms possibly underlying atypical fractures. 2015, 48, 883-94 Bisphosphonates and Atypical Femoral Fractures. 2015, 11, 389-396 Atypical femur fracture during bisphosphonate drug holiday: a case series. 2015, 26, 1755-8	1 20 1
937 936 935 934 933	Atypical Subtrochanteric Femoral Fracture Below an Arthritic Hip: A Case Report. 2015, 5, e1 American Society of Biomechanics Journal of Biomechanics Award 2013: cortical bone tissue mechanical quality and biological mechanisms possibly underlying atypical fractures. 2015, 48, 883-94 Bisphosphonates and Atypical Femoral Fractures. 2015, 11, 389-396 Atypical femur fracture during bisphosphonate drug holiday: a case series. 2015, 26, 1755-8 Right thigh pain. 2015, 44, 763-764 Prodromal Symptoms in Patients with Bisphosphonate-Associated Atypical Fractures of the Femur.	1 20 1 11

929	Short-term and long-term effects of osteoporosis therapies. 2015 , 11, 418-28	117
928	Osteoporosis: screening, prevention, and management. 2015 , 99, 587-606	87
927	Current approaches to osteoporosis treatment. 2015 , 27, 216-24	32
926	Bone microdamage, remodeling and bone fragility: how much damage is too much damage?. 2015 , 4, 644	59
925	Alendronate treatment alters bone tissues at multiple structural levels in healthy canine cortical bone. 2015 , 81, 352-363	45
924	Atypical fractures of the femur: effect of anterolateral bowing of the femur on fracture location. 2015 , 135, 1485-90	29
923	Management of bone disease in women after breast cancer. 2015 , 18 Suppl 2, 47-55	17
922	The safety and tolerability profile of therapies for the prevention and treatment of osteoporosis in postmenopausal women. 2015 , 8, 769-84	37
921	Bisphosphonate drug holidayswhen, why and for how long?. 2015 , 18 Suppl 2, 32-8	17
920	Atypical femoral fracture: report of a case and a hypothesis as to the pathophysiology. 2015 , 63, 827-9	
920	Atypical femoral fracture: report of a case and a hypothesis as to the pathophysiology. 2015 , 63, 827-9 How Long to Treat with Denosumab. 2015 , 13, 415-20	6
		6
919	How Long to Treat with Denosumab. 2015 , 13, 415-20 Can't Catch a Break: Try Using Anti-Osteoporotic Therapy: Commentary on an article by Harpreet S. Bawa, MD, et al.: "Anti-Osteoporotic Therapy After Fragility Fracture Lowers Rate of Subsequent	
919	How Long to Treat with Denosumab. 2015, 13, 415-20 Can't Catch a Break: Try Using Anti-Osteoporotic Therapy: Commentary on an article by Harpreet S. Bawa, MD, et al.: "Anti-Osteoporotic Therapy After Fragility Fracture Lowers Rate of Subsequent Fracture: Analysis of a Large Population Sample". 2015, 97, e65 Exon array analysis reveals genetic heterogeneity in atypical femoral fractures. A pilot study. 2015,	1
919 918 917	How Long to Treat with Denosumab. 2015, 13, 415-20 Can't Catch a Break: Try Using Anti-Osteoporotic Therapy: Commentary on an article by Harpreet S. Bawa, MD, et al.: "Anti-Osteoporotic Therapy After Fragility Fracture Lowers Rate of Subsequent Fracture: Analysis of a Large Population Sample". 2015, 97, e65 Exon array analysis reveals genetic heterogeneity in atypical femoral fractures. A pilot study. 2015, 409, 45-50	1
919 918 917 916	How Long to Treat with Denosumab. 2015, 13, 415-20 Can't Catch a Break: Try Using Anti-Osteoporotic Therapy: Commentary on an article by Harpreet S. Bawa, MD, et al.: "Anti-Osteoporotic Therapy After Fragility Fracture Lowers Rate of Subsequent Fracture: Analysis of a Large Population Sample". 2015, 97, e65 Exon array analysis reveals genetic heterogeneity in atypical femoral fractures. A pilot study. 2015, 409, 45-50 New insights into treatment of osteoporosis in postmenopausal women. 2015, 1, e000051	1 19 18
919 918 917 916 915	How Long to Treat with Denosumab. 2015, 13, 415-20 Can't Catch a Break: Try Using Anti-Osteoporotic Therapy: Commentary on an article by Harpreet S. Bawa, MD, et al.: "Anti-Osteoporotic Therapy After Fragility Fracture Lowers Rate of Subsequent Fracture: Analysis of a Large Population Sample". 2015, 97, e65 Exon array analysis reveals genetic heterogeneity in atypical femoral fractures. A pilot study. 2015, 409, 45-50 New insights into treatment of osteoporosis in postmenopausal women. 2015, 1, e000051 The use of bisphosphonates in women: when to use and when to stop. 2015, 16, 2409-21	1 19 18

911	Evaluating and mitigating fracture risk in established rheumatoid arthritis. 2015, 29, 614-27	15
910	Finite element models predict the location of microdamage in cancellous bone following uniaxial loading. 2015 , 48, 4142-4148	16
909	[Proximal femoral fractures in the elderly]. 2015 , 48, 647-59; quiz 660-1	6
908	Parathyroid Hormone as Monotherapy for the Treatment of Osteoporosis. 2015 , 843-852	
907	Clinical Skeletal Syndromes Associated with Parathyroid Disorders in Chronic Kidney Disease. 2015 , 653-669	
906	Management of postmenopausal osteoporosis. 2015 , 66, 329-42	53
905	Contemporary management of subtrochanteric fractures. 2015 , 46, 21-35	34
904	The effect of parathyroid hormone and teriparatide on fracture healing. 2015 , 15, 119-29	34
903	Duration-dependent effects of clinically relevant oral alendronate doses on cortical bone toughness in beagle dogs. 2015 , 71, 58-62	25
902	Cortical thickness of the femur and long-term bisphosphonate use. <i>Journal of Bone and Mineral Research</i> , 2015 , 30, 225-31	17
901	Effects of long-term alendronate treatment on postmenopausal osteoporosis bone material properties. 2015 , 26, 339-52	22
900	Low-energy femoral shaft fractures after long-term alendronate therapy: report of seven cases. 2015 , 25, 181-7	5
899	The incidence of and risk factors for developing atypical femoral fractures in Japan. 2015, 33, 311-8	42
898	Dual-Energy X-Ray Absorptiometry: Beyond Bone Mineral Density Determination. 2016 , 31, 25-30	26
897	Atypical periprosthetic acetabular fracture in long-term alendronate therapy. 2016 , 13, 209-213	8
896	Pharmacologic treatment of osteoporosis. 2016 , 59, 847	1
895	Difference in Bone Mineral Density Change at the Lateral Femoral Cortices according to Administration of Different Bisphosphonate Agents. 2016 , 23, 85-93	
894	The Role of the Immune System in the Development of Osteoporosis and Fracture Risk. 2016 , 187-214	2

893	Insufficiency Fracture of the Femoral Neck after Intramedullary Nailing for the Treatment of Atypical Femoral Fracture: A Case Report. 2016 , 29, 258	
892	Adjuvant Teriparatide Therapy for Surgical Treatment of Femoral Fractures; Does It Work?. 2016 , 28, 148-156	17
891	Demineralized Bone Matrix Add-On for Acceleration of Bone Healing in Atypical Subtrochanteric Femoral Fracture: A Consecutive Case-Control Study. 2016 , 2016, 4061539	9
890	Total Hip Arthroplasty for Implant Rupture after Surgery for Atypical Subtrochanteric Femoral Fracture. 2016 , 2016, 7146419	1
889	An Evaluative History of Bisphosphonate Drugs: Dual Physiologic Effects of Pyrophosphate as Inspiration for a Novel Pharmaceutical Class. 2016 , 2016, 1426279	2
888	Atypical Complete Femoral Fractures Associated with Bisphosphonate Use or Not Associated with Bisphosphonate Use: Is There a Difference?. 2016 , 2016, 4753170	3
887	Osteoporosis and Bone Biology. 2016 , 1323-1364	5
886	Osteoporosis treatment: a missed opportunity. 2016 , 205, 185-90	27
885	Study of Atypical Femoral Fracture Cases Coupled in a Multicenter Study. 2016 , 38, 207-14	4
884	Healing Time and Complications in Operatively Treated Atypical Femur Fractures Associated With Bisphosphonate Use: A Multicenter Retrospective Cohort. 2016 , 30, 177-81	45
883	Recurrent Proximal Femur Fractures in a Teenager With Osteogenesis Imperfecta on Continuous Bisphosphonate Therapy: Are We Overtreating?. <i>Journal of Bone and Mineral Research</i> , 2016 , 31, 1449-54.3	27
882	A Review of Atypical Femoral Fractures From a Tertiary Care Teaching Hospital: An Alarming Trend?. 2016 , 30, 182-8	7
881	Unusual Femur Stress Fractures in Children With Osteogenesis Imperfecta and Intramedullary Rods on Long-term Intravenous Pamidronate Therapy. 2016 , 36, 757-61	13
880	Protection From Glucocorticoid-Induced Osteoporosis by Anti-Catabolic Signaling in the Absence of Sost/Sclerostin. <i>Journal of Bone and Mineral Research</i> , 2016 , 31, 1791-1802	69
879	Progression of bisphosphonate-associated impending atypical femoral fracture despite prophylactic cephalomedullary nailing: A case report and review of literature. 2016 , 7, 92-98	3
878	Trends in the incidence of atypical femoral fractures and bisphosphonate therapy. 2016 , 24, 36-40	8
877	Ostòporose pendant la mhopause. 2016 , 38, S465-S483	
876	Protocol for a randomized controlled trial to compare bone-loading exercises with risedronate for preventing bone loss in osteopenic postmenopausal women. 2016 , 16, 59	8

(2016-2016)

875	Management of atypical femoral fracture: a scoping review and comprehensive algorithm. 2016 , 17, 227		32
874	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016. 2016 , 22, 1-42		314
873	Bisphosphonate related osteonecrosis of the jaws (BRONJ) in osteoporotic males. 2016 , 5, 1468		
872	Bisphosphonates Are Not Always Helpful: Commentary on an article by Hae-Seong Lim, MD, et al.: "Factors Associated with Increased Healing Time in Complete Femoral Fractures After Long-Term Bisphosphonate Therapy". 2016 , 98, e107		2
871	Osteoporosis: advances in risk assessment and management. 2016 , 16, s121-s124		8
870	Thai Osteoporosis Foundation (TOPF) position statements on management of osteoporosis. 2016 , 2, 191-207		19
869	Femoral Fractures Following Long-term Bisphosphonate Use. 2016 , 39, e1036-e1040		3
868	Factors Associated with Increased Healing Time in Complete Femoral Fractures After Long-Term Bisphosphonate Therapy. 2016 , 98, 1978-1987		37
867	Bisphosphonates and atypical femoral fractures. 2016 , 23, 430-434		8
866	Musculoskeletal injuries in the elderly. 2016 , 462-476		
865	Surgical tips of intramedullary nailing in severely bowed femurs in atypical femur fractures: Simulation with 3D printed model. <i>Injury</i> , 2016 , 47, 1318-24	2.5	38
864	Bilateral atypical femoral fracture and end-stage arthritis of the hip, treated with total hip arthroplasty. 2016 , 2, 147-152		2
863			9
	A summary of the Malaysian Clinical Guidance on the management of postmenopausal and male		9
863	A summary of the Malaysian Clinical Guidance on the management of postmenopausal and male osteoporosis, 2015. 2016 , 2, 1-12		9
86 ₃	A summary of the Malaysian Clinical Guidance on the management of postmenopausal and male osteoporosis, 2015. 2016 , 2, 1-12 Evaluation of Common Fractures of the Hip in the Elderly. 2016 , 5, 38-43 The advantages of tomosynthesis for evaluating bisphosphonate-related atypical femur fractures		
86 ₃ 86 ₂ 86 ₁	A summary of the Malaysian Clinical Guidance on the management of postmenopausal and male osteoporosis, 2015. 2016 , 2, 1-12 Evaluation of Common Fractures of the Hip in the Elderly. 2016 , 5, 38-43 The advantages of tomosynthesis for evaluating bisphosphonate-related atypical femur fractures compared to radiography. 2016 , 45, 615-23		9
863862861860	A summary of the Malaysian Clinical Guidance on the management of postmenopausal and male osteoporosis, 2015. 2016, 2, 1-12 Evaluation of Common Fractures of the Hip in the Elderly. 2016, 5, 38-43 The advantages of tomosynthesis for evaluating bisphosphonate-related atypical femur fractures compared to radiography. 2016, 45, 615-23 Evaluation and Treatment of Osteoporosis. 2016, 100, 807-26 The association of race/ethnicity and risk of atypical femur fracture among older women receiving		9

857	Strains caused by daily loading might be responsible for delayed healing of an incomplete atypical femoral fracture. 2016 , 88, 125-130		13
856	Atypical femoral fracture post total hip replacement in a patient with hip osteoarthritis and an ipsilateral cortical thickening. 2016 , 26, e19-23		7
855	Phenotypic variability in patients with osteogenesis imperfecta caused by BMP1 mutations. 2016 , 170, 3150-3156		23
854	Localized cortical thickening of the femoral diaphysis captured on an X-ray before alendronate therapy in two cases of atypical femoral fracture. 2016 , 45, 1403-7		1
853	Atypical Femoral Fracture Alert Program. 2016 , 67, 304-5		
852	Bone turnover markers and the factors associated with atypical femur fractures among Japanese patients. <i>Injury</i> , 2016 , 47, 2484-2489	2.5	7
851	Fracture atypique fîmorale chez une patiente de 51ans, rîvîant une hypophosphatasie. 2016 , 83, 304-306		
850	Osteogenesis imperfecta in children and adolescents-new developments in diagnosis and treatment. 2016 , 27, 3427-3437		102
849	Bone Biomechanics and Bone Quality: Effects of Pharmaceutical Agents Used to Treat Osteoporosis. 2016 , 14, 197-217		6
848	Atypical Femoral Fracture in Rheumatoid Arthritis Patients Treated With Bisphosphonates: A Nested Case-Control Study. 2016 , 68, 77-82		8
847	Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. <i>Journal of Bone and Mineral Research</i> , 2016 , 31, 16-35	5.3	348
846	Mortality After Atypical Femoral Fractures: A Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2016 , 31, 491-7	5.3	20
845	Atypical femoral fractures and current management. 2016 , 7, 7-22		10
844	Atypical femur fracture in an adolescent boy treated with bisphosphonates for X-linked osteoporosis based on PLS3 mutation. 2016 , 91, 148-51		20
843	Assessment of the effect of reduced compositional heterogeneity on fracture resistance of human cortical bone using finite element modeling. 2016 , 91, 92-101		22
842	Simultaneous, bilateral, complete atypical femoral fractures after long-term alendronate use. 2016 , 13, 401-3		6
841	Recent advances in the pathogenesis and treatment of osteoporosis. 2016 , 16, 360-4		26
840	The use of finite element analysis to estimate the changing strength of bone following treatment for osteoporosis. 2016 , 27, 2651-2654		6

(2016-2016)

839	Role of Side Effects, Physician Involvement, and Patient Perception in Non-Adherence with Oral Bisphosphonates. 2016 , 33, 1374-84		18
838	Treatment of Osteoporosis in Australian Residential Aged Care Facilities: Update on Consensus Recommendations for Fracture Prevention. 2016 , 17, 852-9		19
837	Controversies in osteoporosis management. 2016 , 46, 767-70		1
836	Patients Receiving Parenteral Bisphosphonates for Malignant Disease and Having Developed an Atypical Femoral Fracture Are at Risk of Concomitant Osteonecrosis of the Jaw: An Evidence-Based Review. 2016 , 74, 2403-2408		12
835	Postmenopausal osteoporosis. 2016 , 2, 16069		263
834	Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study. 2016 , 353, i3365		55
833	Atypical Femur Fractures Associated With Diphosphonate Use. 2016 , 24, e20		1
832	Office care of breast disorders. 367-379		
831	Osteoporosis and osteopenia. 468-482		
830	Hypophosphatasia and the risk of atypical femur fractures: a case-control study. 2016 , 17, 332		17
830 829	Hypophosphatasia and the risk of atypical femur fractures: a case-control study. 2016 , 17, 332 Study Explores Potential Trends in Bisphosphonate Use and Atypical Femoral Fracture Risk. 2016 , 22, 85-89		17
	Study Explores Potential Trends in Bisphosphonate Use and Atypical Femoral Fracture Risk. 2016 ,		17 4
829	Study Explores Potential Trends in Bisphosphonate Use and Atypical Femoral Fracture Risk. 2016 , 22, 85-89 Long-term oral bisphosphonate use in relation to fracture risk in postmenopausal women with	6.3	
829	Study Explores Potential Trends in Bisphosphonate Use and Atypical Femoral Fracture Risk. 2016, 22, 85-89 Long-term oral bisphosphonate use in relation to fracture risk in postmenopausal women with breast cancer: findings from the Women's Health Initiative. 2016, 23, 1168-1175 Incidence and Characteristics of Atypical Femoral Fractures: Clinical and Geometrical Data. <i>Journal</i>	6.3	4
829 828 827	Study Explores Potential Trends in Bisphosphonate Use and Atypical Femoral Fracture Risk. 2016, 22, 85-89 Long-term oral bisphosphonate use in relation to fracture risk in postmenopausal women with breast cancer: findings from the Women's Health Initiative. 2016, 23, 1168-1175 Incidence and Characteristics of Atypical Femoral Fractures: Clinical and Geometrical Data. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 767-76	6.3	4 48
829 828 827 826	Study Explores Potential Trends in Bisphosphonate Use and Atypical Femoral Fracture Risk. 2016, 22, 85-89 Long-term oral bisphosphonate use in relation to fracture risk in postmenopausal women with breast cancer: findings from the Women's Health Initiative. 2016, 23, 1168-1175 Incidence and Characteristics of Atypical Femoral Fractures: Clinical and Geometrical Data. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 767-76 Current Controversies in the Management of Myeloma Bone Disease. 2016, 231, 2374-9 Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated	6.3	4 48 26
829 828 827 826	Study Explores Potential Trends in Bisphosphonate Use and Atypical Femoral Fracture Risk. 2016, 22, 85-89 Long-term oral bisphosphonate use in relation to fracture risk in postmenopausal women with breast cancer: findings from the Women's Health Initiative. 2016, 23, 1168-1175 Incidence and Characteristics of Atypical Femoral Fractures: Clinical and Geometrical Data. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 767-76 Current Controversies in the Management of Myeloma Bone Disease. 2016, 231, 2374-9 Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates. 2016, 101, 3163-70	6.3	4 48 26

821	What we don't know about osteoporosis. 2016 , 39, 491-3		9
820	Therapeutic holidays in osteoporosis: Long-term strategy of treatment with bisphosphonates. 2016 , 146, 24-29		
819	Periprosthetic Femoral Stress Fracture After Bisphosphonate Treatment Resulting in Nonunion Successfully Treated with Teriparatide: A Case Report. 2016 , 6, e37		2
818	The cumulative incidence of and risk factors for latent beaking in patients with autoimmune diseases taking long-term glucocorticoids and bisphosphonates. 2016 , 27, 1217-1225		17
817	Incidence of Atypical Femur Fractures in Cancer Patients: The MD Anderson Cancer Center Experience. <i>Journal of Bone and Mineral Research</i> , 2016 , 31, 1569-76	6.3	36
816	Factors related to curved femur in elderly Japanese women. 2016 , 121, 170-3		6
815	Periprosthetic Atypical Femoral Fractures in Patients on Long-term Bisphosphonates: A Multicenter Retrospective Review. 2016 , 30, 170-6		26
814	Clinical, biochemical and genetic spectrum of low alkaline phosphatase levels in adults. 2016 , 29, 40-5		43
813	Assessment of femur geometrical parameters using EOSIImaging technology in patients with atypical femur fractures; preliminary results. 2016 , 83, 184-189		26
812	Clinical Practice. Postmenopausal Osteoporosis. <i>New England Journal of Medicine</i> , 2016 , 374, 254-62	59.2	675
811	Bisphosphonates, Denosumab, and Anabolic Agents in the Treatment of Metastatic Bone Disease. 2016 , 121-129		1
810	Proceedings of the 2015 Santa Fe Bone Symposium: Clinical Applications of Scientific Advances in Osteoporosis and Metabolic Bone Disease. 2016 , 19, 102-16		4
809	Atypical femoral fracture in a 51-year-old woman: Revealing a hypophosphatasia. 2016 , 83, 346-8		15
808	Genetic and acquired factors influencing the effectiveness and toxicity of drug therapy in osteoporosis. 2016 , 12, 389-98		12
807	Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis. 2016 , 39, 807-34		31
806	Risks and Benefits of Bisphosphonate Therapies. 2016 , 117, 20-8		76
805	2016 IMS Recommendations on women's midlife health and menopause hormone therapy. 2016 , 19, 109-50		470
804	Atypical fractures, a biased perspective. <i>Injury</i> , 2016 , 47 Suppl 1, S28-30	2.5	3

(2017-2016)

	a Drug Holiday. 2016 , 12, 66-73	15
802	Recurrence of bilateral atypical femoral fractures associated with the sequential use of teriparatide and denosumab: a case report. 2016 , 27, 821-5	15
801	Audit of Atypical Femoral Fractures and a Description of Some of Their Features. 2016, 67, 69-75	5
800	Long-Term Efficacy and Safety of Treatments for Osteoporosis. 2016 , 203-232	
799	Compliance with established guidelines for the radiological reporting of atypical femoral fractures. 2016 , 89, 20150443	9
798	Atypical femur fractures in patients receiving bisphosphonate therapy: etiology and management. 2016 , 26, 371-7	8
797	Bilateral distal fibula fractures in a woman on long-term bisphosphonate therapy. 2016 , 27, 833-6	4
796	Safety issues and adverse reactions with osteoporosis management. 2016 , 15, 321-32	26
795	Antiresorptives. 2016 , 695-705	
794	Efficacy of recreational football on bone health, body composition, and physical functioning in men with prostate cancer undergoing androgen deprivation therapy: 32-week follow-up of the FC prostate randomised controlled trial. 2016 , 27, 1507-1518	51
793	[Therapeutic holidays in osteoporosis: Long-term strategy of treatment with bisphosphonates]. 2016 , 146, 24-9	3
792	Simultaneous bilateral atypical femoral fracture in a patient receiving denosumab: case report and literature review. 2016 , 27, 827-32	43
79 ²		43
	literature review. 2016 , 27, 827-32	
791	literature review. 2016 , 27, 827-32 Factors associated with atypical femoral fracture. 2016 , 36, 65-71 Atypical Femoral Fractures-Ongoing and History of Bone-Specific Therapy, Concomitant Diseases,	15
79 ¹	Factors associated with atypical femoral fracture. 2016 , 36, 65-71 Atypical Femoral Fractures-Ongoing and History of Bone-Specific Therapy, Concomitant Diseases, Medications, and Survival. 2016 , 19, 359-67	15 6
791 790 789	Factors associated with atypical femoral fracture. 2016 , 36, 65-71 Atypical Femoral Fractures-Ongoing and History of Bone-Specific Therapy, Concomitant Diseases, Medications, and Survival. 2016 , 19, 359-67 Radiology of Osteoporosis. 2016 , 67, 28-40 Epidemiology and Postoperative Outcomes of Atypical Femoral Fractures in Older Adults: A	15 6 24

785	Tratamento da osteoporose pʿB-menopʿŪsica: um algoritmo baseado na literatura para uso no sistema pb̃lico de sade. 2017 , 57, 254-263	4
7 ⁸ 4	Understanding Bone Strength Is Not Enough. <i>Journal of Bone and Mineral Research</i> , 2017 , 32, 1157-11626. ₃	47
783	Responses to Treatment With Teriparatide in Patients With Atypical Femur Fractures Previously Treated With Bisphosphonates. <i>Journal of Bone and Mineral Research</i> , 2017 , 32, 1027-1033	44
782	Incidence and medical management of bisphosphonate-associated atypical femoral fractures in a major trauma centre: a retrospective observational study. 2017 , 18, 29	7
781	Atypical femoral fractures mimicking metastatic lesions in 2 patients taking denosumab. 2017 , 88, 351-353	14
780	Bone Structure and Turnover Status in Postmenopausal Women with Atypical Femur Fracture After Prolonged Bisphosphonate Therapy. 2017 , 100, 235-243	11
779	Atypical femoral shaft fractures secondary to long-term bisphosphonate therapy. 2017 , 14, 226-230	6
778	Osteoporosis: Treat-to-Target. 2017 , 15, 103-109	13
777	Comments on Kamimura et al.: significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients. 2017 , 28, 1755-1756	1
776	Atypical femoral fractures related to bisphosphonate treatment: issues and controversies related to their surgical management. 2017 , 99-B, 295-302	72
775	Local bisphosphonate reduces migration and formation of radiolucent lines adjacent to cemented acetabular components. 2017 , 99-B, 317-324	15
774	Clinical management and pathogenesis of atypical fractures of the femur. 2017 , 99-B, 291-294	4
773	Skeletal Fragility, a Common Menopausal Burden: Risk Assessment, Diagnosis, and Management. 2017 , 145-164	
772	A new contralateral atypical femoral fracture despite sequential therapy with teriparatide and strontium ranelate. 2017 , 6, 34-37	10
771	Utilisation des bisphosphonates pour la consolidation des fractures de fatigue dans la maladie de Paget. 2017 , 84, 252	
770	Antenatal corticosteroids. 2017 , 189, E319	1
769	Surgical outcome of intramedullary nailing in patients with complete atypical femoral fracture: A multicenter retrospective study. <i>Injury</i> , 2017 , 48, 941-945	26
768	Long-term effects of bisphosphonate therapy: perforations, microcracks and mechanical properties. 2017 , 7, 43399	41

767	Long-Term Randomized Trial of Intensive Versus Symptomatic Management in Paget's Disease of Bone: The PRISM-EZ Study. <i>Journal of Bone and Mineral Research</i> , 2017 , 32, 1165-1173	35
766	The British Menopause Society and Women's Health Concern recommendations on the management of women with premature ovarian insufficiency. 2017 , 23, 22-35	44
765	High and pointed type of femoral localized reaction frequently extends to complete and incomplete atypical femoral fracture in patients with autoimmune diseases on long-term glucocorticoids and bisphosphonates. 2017 , 28, 2367-2376	8
764	Iron-induced hypophosphatemia: an emerging complication. 2017 , 26, 266-275	87
763	Identifying Incomplete Atypical Femoral Fractures With Single-Energy Absorptiometry: Declining Prevalence. 2017 , 1, 211-220	8
762	UK clinical guideline for the prevention and treatment of osteoporosis. 2017 , 12, 43	453
761	Intramedullary Nail Fixation of Atypical Femur Fractures With Bone Marrow Aspirate Concentrate Leads to Faster Union: A Case-Control Study. 2017 , 31, 358-362	17
760	Treating Paget's Disease-Why and How Much?. <i>Journal of Bone and Mineral Research</i> , 2017 , 32, 1163-116 8 .3	7
759	Atypical femoral fracture. 2017 , 189, E542	10
758	Retrospective review of patients with atypical bisphosphonate related proximal femoral fractures. <i>Injury</i> , 2017 , 48, 1159-1164	13
757	Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement. 2017 , 101, 23-30	71
756	Undisturbed local bone formation capacity in patients with atypical femoral fractures: a case series. 2017 , 28, 2439-2444	9
755	Intramedullary Nailing for Atypical Femoral Fracture with Excessive Anterolateral Bowing. 2017, 99, 726-735	36
754	Medication management after intramedullary nailing of atypical fractures. <i>Injury</i> , 2017 , 48 Suppl 1, S15-S <u>গ</u> ু	4
753	Intermittent Parathyroid Hormone After Prolonged Alendronate Treatment Induces Substantial New Bone Formation and Increases Bone Tissue Heterogeneity in Ovariectomized Rats. <i>Journal of Bone and Mineral Research</i> , 2017 , 32, 1703-1715	7
752	Non-BMD DXA measurements of the hip. 2017 , 104, 73-83	6
75 ¹	GGPS1 Mutation and Atypical Femoral Fractures with Bisphosphonates. <i>New England Journal of Medicine</i> , 2017 , 376, 1794-1795	32
750	Screening for Atypical Femur Fractures Using Extended Femur Scans by DXA. <i>Journal of Bone and Mineral Research</i> , 2017 , 32, 1632-1639	22

749	A Subtrochanteric Femoral Stress Fracture following Bisphosphonate Treatment in an Adolescent Girl. 2017 , 87, 69-72	9
748	Diabetes, bone and glucose-lowering agents: clinical outcomes. 2017 , 60, 1170-1179	39
747	Arthrotomy-based preclinical models of particle-induced osteolysis: A systematic review. 2017 , 35, 2595-2605	12
746	Bone Lining Cells: Normal Physiology and Role in Response to Anabolic Osteoporosis Treatments. 2017 , 3, 79-84	6
745	10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. 2017 , 5, 513-523	419
744	FDG PET/CT Assesses the Risk of Femoral Pathological Fractures in Patients With Metastatic Breast Cancer. 2017 , 42, 264-270	12
743	Raloxifene Improves Bone Mechanical Properties in Mice Previously Treated with Zoledronate. 2017 , 101, 75-81	7
742	Bone turnover and periprosthetic bone loss after cementless total hip arthroplasty can be restored by zoledronic acid: a prospective, randomized, open-label, controlled trial. 2017 , 18, 209	19
741	Impending Atypical Femoral Fracture in Patients With Medullary Thyroid Cancer With Skeletal Metastasis Treated With Long-term Bisphosphonate and Denosumab. 2017 , 42, 463-464	5
740	Long-Term Oral Bisphosphonate Therapy and Fractures in Older Women: The Women's Health Initiative. 2017 , 65, 1924-1931	6
739	Factors affecting fracture location in atypical femoral fractures: A cross-sectional study with 147 patients. <i>Injury</i> , 2017 , 48, 1570-1574	34
738	Bisphosphonate Treatment and the Characteristics of Femoral Fractures in Children With Osteogenesis Imperfecta. 2017 , 102, 1333-1339	11
737	Presence of pyrophosphate in bone from an atypical femoral fracture site: A case report. 2017 , 6, 81-86	7
736	Bisphosphonates and atypical subtrochanteric fractures of the femur. 2017 , 6, 144-153	27
735	Atraumatic segmental atypical femur fracture secondary to bisphosphonate use: A case report. 2017 , 8, S67-S71	1
734	The Pharmacological Profile of a Novel Highly Potent Bisphosphonate, OX14 (1-Fluoro-2-(Imidazo-[1,2-Pyridin-3-yl)-Ethyl-Bisphosphonate). <i>Journal of Bone and Mineral</i> 6.3 **Research*, 2017 , 32, 1860-1869	18
733	Western Osteoporosis Alliance Clinical Practice Series: Evaluating the Balance of Benefits and Risks of Long-Term Osteoporosis Therapies. 2017 , 130, 862.e1-862.e7	14
73 ²	Healing of Atypical Subtrochanteric Femur Fractures After Cephalomedullary Nailing: Which Factors Predict Union?. 2017 , 31, 138-145	30

731	Osteoporosis: a discussion on the past 5 years. 2017 , 10, 265-274	17
730	Traitements anti-rŝorptifs pour le traitement et la prvention des mtastases osseuses. 2017, 84, 167-173	
729	Retrospective Review of Atypical Femoral Fracture in Metastatic Bone Disease Patients Receiving Denosumab Therapy. 2017 , 22, 438-444	28
728	Femur shaft complete fractures associated with misdiagnosed stress fractures due to bisphosphonates. 2017 , 8, 168-170	1
727	Treatment of postmenopausal osteoporosis: a literature-based algorithm for use in the public health care system. 2017 , 57, 254-263	2
726	Diaphyseal Femur Fractures in Osteogenesis Imperfecta: Characteristics and Relationship With Bisphosphonate Treatment. <i>Journal of Bone and Mineral Research</i> , 2017 , 32, 1034-1039	24
725	Identification of a p.Arg708Gln variant in COL1A2 in atypical femoral fractures. 2017, 84, 715-718	13
724	Addressing the Crisis in the Treatment of Osteoporosis: A Path Forward. <i>Journal of Bone and Mineral Research</i> , 2017 , 32, 424-430	91
723	Chronic kidney disease and fragility fracture. 2017 , 21, 46-52	28
722	Atypical femoral fracture after receiving antiresorptive drugs in breast cancer patients with bone metastasis. 2017 , 24, 601-607	17
721	Prevention and management of glucocorticoid-induced side effects: A comprehensive review: A review of glucocorticoid pharmacology and bone health. 2017 , 76, 1-9	81
720	Metabolic Bone Diseases and Total Hip Arthroplasty: Preventing Complications. 2017 , 25, 725-735	7
719	Antiresorptives: Safety Concerns-Clinical Perspective. 2017 , 45, 859-863	7
718	Denosumab treatment in postmenopausal women with osteoporosis - Authors' reply. 2017 , 5, 768-769	4
717	T-Score Discordance of Bone Mineral Density in Patients with Atypical Femoral Fracture. 2017 , 99, 1683-1688	4
716	Animal Models in Bone Research. 2017 , 129-171	3
715	Brazilian guidelines for the diagnosis and treatment of postmenopausal osteoporosis. 2017 , 57 Suppl 2, 452-466	14
714	Hip Injury: MRI Pitfalls. 2017 , 391-414	

713	Insufficiency Fracture Occurring 3 Years After Union of an Intertrochanteric Hip Fracture: A Case Report. 2017 , 7, e1		2
712	Long-Term Bisphosphonate Therapy in Osteogenesis Imperfecta. 2017 , 15, 412-418		37
711	Atypical femoral fracture associated with bone-modifying agent for bone metastasis of breast cancer: A report of two cases. 2017 , 25, 2309499017727916		10
710	Evaluating Atypical Features of Femur Fractures: How Change in Radiological Criteria Influenced Incidence and Demography of Atypical Femur Fractures in a Community Setting. <i>Journal of Bone and Mineral Research</i> , 2017 , 32, 2304-2314	6.3	21
709	Trends in post osteoporotic hip fracture care from 2010 to 2014 in a private hospital in Malaysia. 2017 , 3, 112-116		5
708	Diretrizes brasileiras para o diagn\(\mathbb{E}\)tico e tratamento da osteoporose em mulheres na p\(\mathbb{E}\)-menopausa. 2017 , 57, 452-466		22
707	The incidence of atypical femoral fractures in breast cancer patients with bone metastases who received bisphosphonate treatment. 2017 , 22, 946-950		4
706	Atypical fracture with long-term bisphosphonate therapy is associated with altered cortical composition and reduced fracture resistance. 2017 , 114, 8722-8727		94
7°5	Predisposing factors associated with atypical femur fracture among postmenopausal Korean women receiving bisphosphonate therapy: 8 years' experience in a single center. 2017 , 28, 3251-3259		34
704	Surgical outcomes of intramedullary nailing for diaphyseal atypical femur fractures: is it safe to modify a nail entry in bowed femur?. 2017 , 137, 1515-1522		18
703	Atypical subtrochanteric fractures in Korean hip fracture study. 2017 , 28, 2853-2858		10
702	Lateral Cortical Thickening and Bone Heterogeneity of the Subtrochanteric Femur Measured With Quantitative CT as Indicators for Early Detection of Atypical Femoral Fractures in Long-Term Bisphosphonate Users. 2017 , 209, 867-873		8
701	Histomorphometric and osteocytic characteristics of cortical bone in male subtrochanteric femoral shaft. 2017 , 231, 708-717		5
700	Atypical femur fractures: a survey of current practices in orthopedic surgery. 2017 , 28, 3271-3276		3
699	Management of Acute Hip Fracture. New England Journal of Medicine, 2017, 377, 2053-2062	59.2	182
698	Postmenopausal Osteoporosis. 2017 , 125-140		1
697	FRATURA ATBICA DE FIMUR EM PACIENTES DE UM SERVID DE REUMATOLOGIA: DADOS CLÍNICOS, RADIOGRÉTICOS E DE HISTOMORFOMETRIA (SSEA. 2017 , 57, S73-S74		
696	Cathepsin K Inhibitors for Osteoporosis: Biology, Potential Clinical Utility, and Lessons Learned. 2017 , 38, 325-350		114

695	Osteoporosis treatment: recent developments and ongoing challenges. 2017 , 5, 898-907	315
694	Selective effect of hydroxyapatite nanoparticles on osteoporotic and healthy bone formation correlates with intracellular calcium homeostasis regulation. 2017 , 59, 338-350	37
693	Osteoporosis Management. 2017 , 26, 918-921	2
692	Assessing the feasibility of the Effectiveness of Discontinuing Bisphosphonates trial: a pilot study. 2017 , 28, 2495-2503	4
691	Bisphosphonates in the treatment of osteoporosis: a review of skeletal safety concerns. 2017 , 12, 59-71	5
690	Atypical femoral fractures in Italy: a retrospective analysis in a large urban emergency department during a 7-year period (2007-2013). 2017 , 35, 562-570	6
689	Outcomes between older adults with atypical and typical femoral fractures are comparable. <i>Injury</i> , 2017 , 48, 394-398	7
688	Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates. 2017 , 28, 1145-1147	18
687	Sensitivity and specificity of radiographic characteristics in atypical femoral fractures. 2017 , 28, 413-417	13
686	Trends in oral anti-osteoporosis drug prescription in the United Kingdom between 1990 and 2012: Variation by age, sex, geographic location and ethnicity. 2017 , 94, 50-55	47
685	Review: Breaking From Bisphosphonates. 2017 , 69, 494-498	
684	PTH(1-34) and zoledronic acid have differing longitudinal effects on juvenile mouse femur strength and morphology. 2017 , 35, 1707-1715	1
683	Efficacy of Osteoporosis Therapies in Diabetic Patients. 2017 , 100, 165-173	25
682	Anterolateral femoral bowing and loss of thigh muscle are associated with occurrence of atypical femoral fracture: Effect of failed tension band mechanism in mid-thigh. 2017 , 22, 99-104	13
681	Double Fixation: Bilateral Bisphosphonate-Related Hip Fractures. 2017 , 130, e13-e15	4
680	Identification and management of osteoporosis in older adults. 2017 , 45, 55-61	
679	Diabetes and Bone Disease. 2017 , 46, 63-85	18
678	Scoring System for Identifying Impending Complete Fractures in Incomplete Atypical Femoral Fractures. 2017 , 102, 545-550	26

677	Denosumab: Prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures. 2017 , 13, 266-276	24
676	Bisphosphonate use in children with cerebral palsy. 2017,	1
675	Efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: A systematic review and meta-analysis. 2017 , 96, e8659	29
674	Non-Operative Treatment. 2017 , 83-95	
673	Idiopathic Osteonecrosis and Atypical Femoral Fracture in Systemic Lupus Erythematosus. 2017,	
672	Mesenchymal stem cells expressing osteoprotegerin variants inhibit osteolysis in a murine model of multiple myeloma. 2017 , 1, 2375-2385	7
671	Paget's Disease: Skeletal Manifestations and Effect of Bisphosphonates. 2017 , 24, 97-103	12
670	Renal Tubular Acidosis in Patients with Primary Sjören's Syndrome. 2017 , 15, 17-22	14
669	Molecular Abnormalities Underlying Bone Fragility in Chronic Kidney Disease. 2017 , 2017, 3485785	8
668	Treatment of Atypical Ulnar Fractures Associated with Long-Term Bisphosphonate Therapy for Osteoporosis: Autogenous Bone Graft with Internal Fixation. 2017 , 2017, 8602573	13
667	Atypical Femoral Shaft Fractures in Female Bisphosphonate Users Were Associated with an Increased Anterolateral Femoral Bow and a Thicker Lateral Cortex: A Case-Control Study. 2017 , 2017, 5932496	11
666	Long-term use of bisphosphonates in osteoporosis. 2017 , 38, 604-608	12
665	Lateral Femoral Bowing and the Location of Atypical Femoral Fractures. 2017, 29, 127-132	25
664	Protective effect of low-dose risedronate against osteocyte apoptosis and bone loss in ovariectomized rats. 2017 , 12, e0186012	11
663	Surgical outcome of atypical subtrochanteric and femoral fracture related to bisphosphonates use in osteoporotic patients with or without teriparatide treatment. 2017 , 18, 527	28
662	Atypical Fracture-Like Insufficiency Fracture of the Tibia with Prolonged Bisphosphonate Drug: A Case Report. 2017 , 30, 137	
661	Denosumab: Renal Safety Evaluation. 2017 , 1, 127-131	
660	Bis-enoxacin blocks alveolar bone resorption in rats with ovariectomy-induced osteoporosis. 2018 , 17, 3232-3238	7

659	Zoledronic acid in pediatric metabolic bone disorders. 2017 , 6, 256-268	16
658	Recent Advances in Understanding Bisphosphonate Effects on Bone Mechanical Properties. 2018 , 16, 198-204	13
657	Influence of geometry on proximal femoral shaft strains: Implications for atypical femoral fracture. 2018 , 110, 295-303	26
656	Intertrochanteric fracture associated with undiagnosed ipsilateral incomplete atypical femoral shaft fracture without bisphosphonate use: Unique case report and literature review. 2018 , 9, S12-S16	
655	A proposal for an atypical femur fracture treatment and prevention clinical practice guideline. 2018 , 29, 1277-1283	17
654	Glucocorticoid-induced osteoporosis: an update. 2018 , 61, 7-16	168
653	The Challenges and Opportunities of Pharmacoepidemiology in Bone Diseases. 2018, 2, 187-194	4
652	Anabolic agents: what is beyond osteoporosis?. 2018 , 29, 1009-1022	19
651	Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. 2018 , 6, 445-454	103
650	Long-term treatment strategies for postmenopausal osteoporosis. 2018 , 30, 420-426	15
649	Update on osteoporosis treatment. 2018 , 150, 479-486	О
648	Osteoporosis: Diagnosis and Management. 2018 , 525-565	3
647	2018 update of French recommendations on the management of postmenopausal osteoporosis. 2018 , 85, 519-530	65
646	Optimizing Sequential and Combined Anabolic and Antiresorptive Osteoporosis Therapy. 2018 , 2, 62-68	39
645	MANAGEMENT OF ENDOCRINE DISEASE: Atypical femoral fractures: risks and benefits of long-term treatment of osteoporosis with anti-resorptive therapy. 2018 , 178, R81-R87	24
644	Osteonecrosis of the Jaw and Rebound Hypercalcemia in Young People Treated With Denosumab for Giant Cell Tumor of Bone. 2018 , 103, 596-603	35
643	Treatment of Adolescent Osteoporosis. 2018 , 243-259	
642	Safety and efficacy of denosumab in osteoporotic patients previously treated with other medications: a systematic review and meta-analysis. 2018 , 17, 413-428	14

641	Atypical fractures: An issue of concern or a myth?. <i>Injury</i> , 2018 , 49, 649-655	2.5	7
640	Atypical femur fracture in a patient with indolent mastocytosis: A case report. 2018, 7, 14-16		
639	Update on osteoporosis treatment. 2018 , 150, 479-486		14
638	A review of atypical subtrochanteric femoral fractures in Northern Ireland between 2010 and 2014. 2018 , 28, 607-613		4
637	[Management of osteoporosis after fragility fractures]. 2018, 51, 113-125		4
636	Proceedings of the 2017 Santa Fe Bone Symposium: Insights and Emerging Concepts in the Management of Osteoporosis. 2018 , 21, 3-21		6
635	How to use bisphosphonates safely and optimally. 2018 , 57, 1875-1876		3
634	Stress and Insufficiency Fractures. 2018 , 16, 3-15		1
633	Critical differences between subtrochanteric and diaphyseal atypical femoral fractures: analyses of 51 cases at a single institution in Korean population. 2018 , 13, 53		6
632	Treatment of osteoporosis: whom, how and for how long?. 2018 , 79, 259-264		4
631	Genetic Risk Factors for Atypical Femoral Fractures (AFFs): A Systematic Review. 2018, 2, 1-11		36
630	Actualisation 2018 des recommandations fran\(\textit{is}\)ises du traitement de l\(\textit{b}\)st\(\textit{p}\)porose post-m\(\textit{n}\)opausique. 2018 , 85, 428-440		5
629	Rare case of atypical femoral fracture with blocked medullary canal associated with bisphosphonate therapy. 2018 , 9, S8-S11		1
628	Postmenopausal Osteoporosis: A Clinical Review. 2018 , 27, 1093-1096		41
627	Glucocorticoid-induced osteoporosis: Short-term and long-term management. 2018, 3, 38-41		O
626	Factors associated with osteoporosis medication initiation and adherence. 2018, 4, 1		
625	Skeletal changes during and after spaceflight. 2018 , 14, 229-245		78
624	Osteogenesis imperfecta - A clinical update. 2018 , 80, 27-37		61

623	Teriparatide for treatment of patients with bisphosphonate-associated atypical fracture of the femur. 2018 , 29, 501-506	29
622	Atraumatic femoral neck fracture during bisphosphonate treatment: case report and review of the literature. 2018 , 30, 881-885	2
621	Treatment status and radiographic features of patients with atypical femoral fractures. 2018, 23, 316-320	5
620	Atypical Fracture of the Ulna Associated with 3 Years of Bisphosphonate Medication. 2018 , 53, 277	
619	Prevention and treatment of osteoporosis in women. 2018 , 24, 167-170	
618	Korean Guideline for the Prevention and Treatment of Glucocorticoid-induced Osteoporosis. 2018 , 25, 263	2
617	Osteoporosis. 2018 , 12, 4062-4074	
616	A Case Series and Discussion on Surgical Treatment Strategy for Atypical Proximal Femoral Fractures Associated with Bisphosphonate Use. 2018 , 10, e3670	3
615	Second Colombian Consensus on the Management of Post-menopausal Osteoporosis: 2017 update. 2018 , 25, 184-210	
614	Outside the Bone: What Is Happening Systemically to Influence Fracture Healing?. 2018 , 32 Suppl 1, S33-S36	11
613	Impending Atypical Femoral Fracture in a Patient of Breast Cancer With Bone Metastases Receiving Long-term Denosumab. 2018 , 43, 365-366	4
612	Endoprosthetic Reconstruction for a Displaced Atypical Femoral Fracture in a Cancer Patient with Poor Prognosis. 2018 , 2018, 7862516	
611	Rethinking Bone Disease in Kidney Disease. 2018 , 2, 309-322	25
610	Imaging Features and Management of Stress, Atypical, and Pathologic Fractures. 2018 , 38, 2173-2192	45
609	Salvage of failed osteosynthesis for an atypical subtrochanteric femoral fracture associated with long-term bisphosphonate treatment using a 95° angled blade plate. 2018 , 100-B, 1511-1517	8
608	Outcomes for Elderly Patients With Atypical Femoral Fractures Compared to Typical Femoral Fractures for Length of Stay, Discharge Destination, and 30-Day Mortality Rate. 2018 , 9, 2151459318820222	3
607	Korean Guideline for the Prevention and Treatment of Glucocorticoid-induced Osteoporosis. 2018 , 25, 195-211	23
606	II Consenso Colombiano para el Manejo de la Osteoporosis Posmenopüsica. 2018 , 25, 184-210	6

605	Hip Fracture Nonunions: Diagnosis, Treatment, and Special Considerations in Elderly Patients. 2018 , 2018, 1912762		5
604	Low Positive Predictive Value of Bone Scan to Predict Impending Complete Fracture among Incomplete Atypical Femoral Fracture. 2018 , 33, e157		1
603	Surgical Treatment of the Atypical Femoral Fracture: Overcoming Femoral Bowing. 2018, 30, 202-209		14
602	Surgical Management of Atypical Femur Fractures Associated With Bisphosphonate Therapy. 2018 , 26, 864-871		11
601	Atypical Femoral Fracture: A Fascinating Story in Evolution. <i>Journal of Bone and Mineral Research</i> , 2018 , 33, 2089-2090	6.3	1
600	Working to Increase Stability through Exercise (WISE): Study protocol for a pragmatic randomized controlled trial of a coached exercise program to reduce serious fall-related injuries. 2018 , 74, 1-10		3
599	The enigma of atypical femoral fractures: A summary of current knowledge. 2018, 3, 494-500		21
598	Fracture Prevention with Zoledronate in Older Women with Osteopenia. <i>New England Journal of Medicine</i> , 2018 , 379, 2407-2416	59.2	174
597	Boldine Ameliorates Estrogen Deficiency-Induced Bone Loss via Inhibiting Bone Resorption. 2018 , 9, 1046		6
596	Bisphosphonates for Postmenopausal Osteoporosis. 2018 , 545-552		1
595	Atypical fractures and molecular environment: What do we know?. <i>Injury</i> , 2018 , 49, 1953-1958	2.5	4
594	[Senescent cells: a target in osteo-articular diseases]. 2018 , 34, 547-553		2
593	Team Approach: Bone Health in Children and Adolescents. 2018 , 6, e6		1
592	Parathyroid Hormone and Abaloparatide Treatment for Osteoporosis. 2018, 559-566		
591	Adverse Effects of Drugs for Osteoporosis. 2018 , 579-587		
590	Atypical Femoral Fractures: What Do We Know about Them?. 2018 , 31, 159		
589	Bone Stress Injuries. 2018 , 450-458		
588	Frequency and associated factor of atypical periprosthetic femoral fracture after hip arthroplasty. <i>Injury</i> , 2018 , 49, 2264-2268	2.5	12

(2018-2018)

587	Functional Characterization of a GGPPS Variant Identified in Atypical Femoral Fracture Patients and Delineation of the Role of GGPPS in Bone-Relevant Cell Types. <i>Journal of Bone and Mineral Research</i> , 2018 , 33, 2091-2098	6.3	12
586	[Trochanteric and subtrochanteric fractures]. 2018 , 89, 837-848		О
585	Atypical Fracture of the Proximal Shaft of the Ulna Associated with Prolonged Bisphosphonate Therapy. 2018 , 10, 389-392		19
584	Interaction of Microcracks and Tissue Compositional Heterogeneity in Determining Fracture Resistance of Human Cortical Bone. 2018 , 140,		3
583	Subtrochanteric and diaphyseal femoral fractures in hypophosphatasia-not atypical at all. 2018 , 29, 181	5-182	5 30
582	Efficacy of teriparatide and denosumab combination treatment in a patient with atypical femoral fracture and Behëtë disease: a case report and review of the literature. 2018 , 2, 92-96		1
581	Update on osteoporosis in men. 2018 , 32, 759-772		25
580	Current Understanding of Epidemiology, Pathophysiology, and Management of Atypical Femur Fractures. 2018 , 16, 519-529		57
579	[Atypical distal tibial shaft fractures in a patient with bilateral TKA and antiresorptive treatment]. 2018 , 47, 688-691		2
578	The Emperor's New Clothes: What Randomized Controlled Trials Don't Cover. <i>Journal of Bone and Mineral Research</i> , 2018 , 33, 1394-1396	6.3	7
577	Wnt signaling in bone metastasis: mechanisms and therapeutic opportunities. 2018, 208, 33-45		8
576	Comparison of Atypical and Osteoporotic Femoral Shaft Fractures in the Elderly: A Multicenter Study. 2018 , 2018, 1068053		3
575	How Would You Manage This Patient With Osteoporosis?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. 2018 , 168, 801-808		5
574	MMP14 is a novel target of PTH signaling in osteocytes that controls resorption by regulating soluble RANKL production. 2018 , 32, 2878-2890		22
573	Bisphosphonate use after clinical fracture and risk of new fracture: response to comments by Wu et al. 2018 , 29, 2159-2160		1
572	Incidence, risk factors, and fracture healing of atypical femoral fractures: a multicenter case-control study. 2018 , 29, 2427-2435		28
571	Prevalence and Risk Factors of Atypical Femoral Fracture Bone Scintigraphic Feature in Patients Experiencing Bisphosphonate-Related Osteonecrosis of the Jaw. 2018 , 52, 311-317		2
570	Tratamiento de la osteoporosis: osteoporosis en la mujer premenoplisica y posmenoplisica. Osteoporosis en el varfi. 2018 , 12, 3506-3514		

569	Incidence Rate of Atypical Femoral Fracture after Bisphosphonates Treatment in Korea. 2018, 33, e38	8
568	The Role of Vitamin D in Orthopedic Surgery. 2018 , 1043-1061	1
567	Radiology of Rickets and Osteomalacia. 2018 , 975-1006	O
566	Advances and Unmet Needs in the Therapeutics of Bone Fragility. 2018, 9, 505	17
565	The effects of teriparatide on acceleration of bone healing following atypical femoral fracture: comparison between daily and weekly administration. 2018 , 29, 2659-2665	18
564	Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study. 2018 , 13, 85	12
563	Menopause and Aging. 2019 , 322-356.e9	6
562	Glucocorticoid-Induced Osteoporosis: Management Challenges in Older Patients. 2019 , 22, 20-24	7
561	Guidelines for the management of osteoporosis and fragility fractures. 2019 , 14, 85-102	104
560	Fragility fractures of the proximal femur: review and update for radiologists. 2019 , 48, 29-45	12
559	Accumulation of microdamage at complete and incomplete fracture sites in a patient with bilateral atypical femoral fractures on glucocorticoid and bisphosphonate therapy. 2019 , 37, 206-211	4
558	The Role of Lower-Limb Geometry in the Pathophysiology of Atypical Femoral Fracture. 2019 , 17, 281-290	15
557	A Periprosthetic Femoral Fracture with Characteristics of Atypical Femoral Fracture. 2019 , 2019, 1275369	4
556	A Retrospective Review on Atypical Femoral Fracture: Operative Outcomes and the Risk Factors for Failure. 2019 , 10, 2151459319864736	5
555	High bisphosphonate treatment rates and the prevalence of atypical femoral fractures in patients with systematic lupus erythematosus: a single-center retrospective study performed in Japan. 2019 , 39, 1803-1810	4
554	Different surgical outcomes in a patient with bilateral atypical femoral fracture related to bisphosphonate use with or without teriparatide treatment. 2019 , 30, 2349-2354	8
553	Natural history of incomplete atypical femoral fractures in patients after a prolonged and variable course of bisphosphonate therapy-a long-term radiological follow-up. 2019 , 30, 2417-2428	7
552	Detection of Atypical Femur Fractures. 2019 , 22, 506-516	9

551 Femurschaftfrakturen. **2019**, 21, 95-103

550	[Atypical fracture of the femur related to prolonged bisphosphonate use. The importance of saying 'enough's enough']. 2019 , 53, 121-125	1
549	Morphological profile of atypical femoral fractures: age-related changes to the cross-sectional geometry of the diaphysis. 2019 , 235, 892-902	4
548	Bisphosphonate use in the horse: what is good and what is not?. 2019 , 15, 211	3
547	Localization of Atypical Femoral Fracture on Straight and Bowed Femurs. 2019 , 26, 123-131	11
546	Strong Bones, Strong Body. 2019 , 46, 541-552	
545	A retrospective bicenter comparative study of surgical outcomes of atypical femoral fracture: Potential effect of teriparatide on fracture healing and callus formation. 2019 , 128, 115033	9
544	Recent advances in functional nanostructured materials for bone-related diseases. 2019 , 7, 509-527	15
543	Atypical Tibial Fracture in a 63-Year-Old Woman With Intermittent Use of Bisphosphonate Unmasking Hypophosphatasia. 2019 , 3, 2082-2087	3
542	Practical management of fracture risk among peri-ʻand postmenopausal women. 2019 , 112, 782-790	1
541	Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. 2019 , 7, 899-911	61
540	Management of glucocorticoid-induced osteoporosis: What is new?. 2019 , 22, 1595-1597	2
539	Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review. 2019 , 19, 980	23
538	Osteoporose: Oberstes Ziel ist die Vermeidung von Frakturen. 2019 , 14, 40-47	
537	Aging Bone, Osteoporosis and Fragility Fracture. 2019,	
536	Systemic delivery of a Gli inhibitor via polymeric nanocarriers inhibits tumor-induced bone disease. 2019 , 311-312, 257-272	12
535	Atypical femoral fractures from bisphosphonate in cancer patients - Review. 2019 , 18, 100259	11
534	Atypical femoral fracture in the setting of alendronate treatment for osteoporosis: a case report and literature review. 2019 , 9, 340-343	1

533	Incomplete atypical femoral fractures after bisphosphonate use in postmenopausal women. 2019 , 27, 2309499019875262	1
532	Atypical femur fracture incidence in women increases with duration of bisphosphonate exposure. 2019 , 30, 2515-2520	11
531	Potential bone fragility of mid-shaft atypical femoral fracture: Biomechanical analysis by a CT-based nonlinear finite element method. <i>Injury</i> , 2019 , 50, 1876-1882	14
530	Antiresorptive-associated spontaneous fractures of both tibiae, followed by an atypical femur fracture during the sequential treatment with alendronate, denosumab then teriparatide. 2019 , 12,	8
529	Osteogenesis Imperfecta: New Perspectives From Clinical and Translational Research. 2019 , 3, e10174	45
528	Mechanisms Underlying Normal Fracture Healing and Risk Factors for Delayed Healing. 2019, 17, 36-47	13
527	Osteoporosis. 2019 , 393, 364-376	578
526	Preventative effects of metformin on glucocorticoid-induced osteoporosis in rats. 2019 , 37, 805-814	11
525	Treating osteoporosis to prevent fractures: current concepts and future developments. 2019 , 285, 381-394	56
524	Bazedoxifene for the treatment of osteoporosis. 2019 , 20, 1201-1210	15
523	Specific RANK Cytoplasmic Motifs Drive Osteoclastogenesis. <i>Journal of Bone and Mineral Research</i> , 2019 , 34, 1938-1951	7
522	Image-based anatomical reconstruction and pharmaco-mediated bone remodeling model applied to a femur with subtrochanteric fracture: A subject-specific finite element study. 2019 , 69, 58-71	6
521	Recommendations by the Spanish Society of Rheumatology on Osteoporosis. 2019 , 15, 188-210	2
520	Chronic anterior tibial stress fractures in athletes: No crack but intense remodeling. 2019 , 29, 1521-1528	10
519	An update on therapies for the treatment of diabetes-induced osteoporosis. 2019 , 19, 937-948	34
518	A Genome-Wide Association Study of Bisphosphonate-Associated Atypical Femoral Fracture. 2019 , 105, 51-67	10
517	Beware of bone pain with bisphosphonates. 2019 , 12,	6
516	Utility of Probiotics for Maintenance or Improvement of Health Status in Older People - A Scoping Review. 2019 , 23, 364-372	8

515	Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline. 2019 , 104, 1595-1622	259
514	Seno-suppressive molecules as new therapeutic perspectives in rheumatic diseases. 2019 , 165, 126-133	4
513	Clinical Update on Osteoporosis. 2019 , 64, 265-275	23
512	Bilateral subtrochanteric femur insufficiency fractures after bariatric surgery: a case report. 2019 , 30, 1317-1320	
511	Reliability and diagnostic utility of radiographs in patients with incomplete atypical femoral fractures. 2019 , 48, 1427-1434	2
510	The next step after anti-osteoporotic drug discontinuation: an up-to-date review of sequential treatment. 2019 , 64, 441-455	10
509	Two Cases of Periprosthetic Atypical Femoral Fractures in Patients on Long-Term Bisphosphonate Treatment. 2019 , 2019, 9845320	6
508	Inter-site Variability of the Human Osteocyte Lacunar Network: Implications for Bone Quality. 2019 , 17, 105-115	14
507	State of the art in osteoporosis risk assessment and treatment. 2019 , 42, 1149-1164	71
506	Glucocorticoid-induced osteoporosis: 2019 concise clinical review. 2019 , 30, 1145-1156	68
505	Proof of Concept on Functionality Improvement of Mesenchymal Stem-Cells, in Postmenopausal Osteoporotic Women Treated with Teriparatide (PTH1-34), After Suffering Atypical Fractures. 2019 , 104, 631-640	3
504	Zoledronic acid for the treatment of prostate cancer. 2019 , 20, 657-666	9
503	Incidence of Mutations in the , , and Genes in Patients With Atypical Femoral Fractures. 2019 , 3, 29-36	14
502	Combating osteoporosis and obesity with exercise: leveraging cell mechanosensitivity. 2019 , 15, 339-355	67
501	Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial. 2019 , 71, 1174-1184	59
500	Osteoporosis. 2019 , 1005-1035	
499	Radiological criteria for atypical features of femur fractures: what we can learn when applied in a clinical study setting. 2019 , 30, 1287-1295	3
498	Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (6), assessment of mandibular metabolism due to long-term administration of an anti-resorptive agent by bone scintigraphy (secondary publication). 2019 , 55, 51-57	2

497	A suspicious atypical fracture of 5th metatarsal bone: A case report. 2019 ,	1
496	Atypical Femur Fractures: Review of Epidemiology, Relationship to Bisphosphonates, Prevention, and Clinical Management. 2019 , 40, 333-368	92
495	A suspicious fracture. 2019 , 64, e3-e4	1
494	Monthly Intramuscular Neridronate for the Treatment of Postmenopausal Osteoporosis: Results of a 6-Year Prospective Italian Study. 2019 , 2019, 9802827	2
493	Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review. 2019 , 171, 37-50	46
492	Periprosthetic atypical femoral fractures exist and are associated with duration of bisphosphonate therapy. 2019 , 101-B, 1285-1291	22
491	Teriparatide Treatment for An Atypical Fracture of the Femoral Shaft: A Case Report. 2019, 31, 73-77	
490	Skeletal Site-Specific Response of Jawbones and Long Bones to Surgical Interventions in Rats Treated with Zoledronic Acid. 2019 , 2019, 5138175	4
489	Case of atypical femoral fractures that mimicked the typical imaging findings of prostate cancer-induced bone metastasis. 2019 , 2, 303-306	1
488	Effects of Intermittent Administration of Parathyroid Hormone and Parathyroid Hormone-Related Protein on Fracture Healing: A Narrative Review of Animal and Human Studies. 2019 , 3, e10250	14
487	Study protocol: design and rationale for an exploratory phase II randomized controlled trial to determine optimal vitamin D supplementation strategies for acute fracture healing. 2019 , 5, 135	4
486	Case Report and Literature Review of Periprosthetic Atypical Femoral Fractures After Total Hip Arthroplasty. 2019 , 41, 409-416	3
485	Prophylactic Fixation Can Be Cost-effective in Preventing a Contralateral Bisphosphonate-associated Femur Fracture. 2019 , 477, 480-490	3
484	Atypical incomplete femoral neck fracture in patients taking long-term bisphosphonate: Case report, a report of 2 cases. 2019 , 98, e14701	7
483	Detection and management of atypical femur fractures. 2019 , 26, 283-290	2
482	Diagnosis and Treatment of Osteoporosis: What Orthopaedic Surgeons Need to Know. 2019 , 27, e902-e912	14
481	Medialized Trochanteric Starting Point and Focused Lateral Endosteal Beak Reaming to Optimize	
401	Success of Intramedullary Nailing in Atypical Femur Fractures: A Technical Trick and Case Series. 2019 , 33, e313-e317	2

(2020-2019)

Editor's Spotlight/Take 5: Prophylactic Fixation Can Be Cost-effective in Preventing a Contralateral Bisphosphonate-associated Femur Fracture. **2019**, 477, 477-479

478	Side effects of drugs for osteoporosis and metastatic bone disease. 2019 , 85, 1063-1071	38
477	Osteoporosis in Older Persons: Old and New Players. 2019 , 67, 831-840	31
476	Radiation-induced insufficiency fracture of the femur 18 years after radiation therapy. 2019 , 14, 179-183	1
475	Bisphosphonates Use and Risk of Subtrochanteric and Diaphyseal Femur Fractures in Korea: Results from the National Claim Registry. 2019 , 104, 313-319	1
474	Do femoral fractures in adult patients with osteogenesis imperfecta imitate atypical femoral fractures? A case series. 2019 , 30, 513-517	3
473	Orthogonal Plating With a 95-Degree Blade Plate for Salvage of Unsuccessful Cephalomedullary Nailing of Atypic Femur Fractures: A Technical Trick. 2019 , 33, e246-e250	4
472	Recommendations by the Spanish Society of Rheumatology on Osteoporosis. 2019 , 15, 188-210	15
471	Intertrochanteric fracture visualization and analysis using a map projection technique. 2019 , 57, 633-642	3
470	Orthopedic Surgery and the Geriatric Patient. 2019 , 35, 65-92	19
469	Osteoporosis: a clinical and pharmacological update. 2019 , 38, 385-395	25
468	Novel mutations in BMP1 induce a rare type of osteogenesis imperfecta. 2019 , 489, 21-28	11
467	Prevalence and Characteristics of Atypical Periprosthetic Femoral Fractures. <i>Journal of Bone and Mineral Research</i> , 2019 , 34, 83-92	17
466	Alendronate improves bone density and type I collagen accumulation but increases the amount of pentosidine in the healing dental alveolus of ovariectomized rabbits. 2019 , 120, 9-19	5
465	The increase in bone mineral density by bisphosphonate with active vitamin D analog is associated with the serum calcium level within the reference interval in postmenopausal osteoporosis. 2019 , 29, 157-164	3
464	Trabecular Bone Score and Hip Structural Analysis in Patients With Atypical Femur Fractures. 2019 , 22, 257-265	5
463	Clinical Pharmacology of Bisphosphonates. 2020 , 579-589	1
462	Bone development and remodeling in metabolic disorders. 2020 , 43, 133-144	9

461	Atypical Femoral Fracture Associated With Overuse of Bisphosphonate Evaluated by High-Resolution Peripheral Quantitative Computed Tomography (HR-pQCT). 2020 , 23, 329-334		1
460	Pretreatment with Pamidronate Decreases Bone Formation but Increases Callus Bone Volume in a Rat Closed Fracture Model. 2020 , 106, 172-179		1
459	Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition. <i>Journal of Bone and Mineral Research</i> , 2020 , 35, 36-52	6.3	63
458	Racial difference in bioavailability of oral ibandronate between Caucasian and Taiwanese postmenopausal women. 2020 , 31, 193-201		2
457	Patient and Caregiver Priorities for Medication Adherence in Gout, Osteoporosis, and Rheumatoid Arthritis: Nominal Group Technique. 2020 , 72, 1410-1419		12
456	Atypical femoral fracture associated with delayed union for which the cessation of alendronate and daily administration of teriparatide contributed to fracture healing: histopathological evidence of the enhancement in bone formation parameters. 2020 , 4, 141-146		3
455	Proceedings of the 2019 Santa Fe Bone Symposium: New Concepts in the Care of Osteoporosis and Rare Bone Diseases. 2020 , 23, 1-20		6
454	Effect of continuous long-term treatment for 10 years with bisphosphonate on Japanese osteoporosis patients. 2020 , 38, 240-247		3
453	Osteoporosis. 2020 , 799-805		1
452	Temporal Trends and Factors Associated with Bisphosphonate Discontinuation and Restart. <i>Journal of Bone and Mineral Research</i> , 2020 , 35, 478-487	6.3	7
451	Pharmacological mechanisms of therapeutics: Receptor activator of nuclear factor lappa B ligand inhibition. 2020 , 1689-1710		1
450	Diabetes and fractures: new evidence of atypical femoral fractures?. 2020 , 31, 447-455		
			8
449	Bisphosphonate therapy in CKD: the current state of affairs. 2020 , 29, 221-226		3
449	Bisphosphonate therapy in CKD: the current state of affairs. 2020 , 29, 221-226 Surgical results of atypical femoral fractures in long-term bisphosphonate and glucocorticoid users - Relationship between fracture reduction and bone union. 2020 , 19, 143-149		
	Surgical results of atypical femoral fractures in long-term bisphosphonate and glucocorticoid users		3
448	Surgical results of atypical femoral fractures in long-term bisphosphonate and glucocorticoid users - Relationship between fracture reduction and bone union. 2020 , 19, 143-149 Efficacy of bone-end intervention on fracture healing in bisphosphonate-related atypical femoral		3 5
448	Surgical results of atypical femoral fractures in long-term bisphosphonate and glucocorticoid users - Relationship between fracture reduction and bone union. 2020 , 19, 143-149 Efficacy of bone-end intervention on fracture healing in bisphosphonate-related atypical femoral fractures. 2020 , 106, 77-83 Importance and Difficulty of Differentiating BMA-induced AFF Prodromal Symptoms from		355

(2020-2020)

443	Bisphosphonate-related atypical femoral fractures: A novel strategy to improve patient outcomes. 2020 , 27, 192-197	1
442	The British Menopause Society & Women's Health Concern 2020 recommendations on hormone replacement therapy in menopausal women. 2020 , 26, 181-209	24
441	Repurposing denosumab in breast cancer beyond prevention of skeletal related events: Could nonclinical data be translated into clinical practice?. 2020 , 13, 1235-1252	
440	The Effects of Calcitonin Gene-Related Peptide on Bone Homeostasis and Regeneration. 2020 , 18, 621-632	4
439	Incidence of atypical femoral fractures in the treatment of bone metastasis: An alert report. 2020 , 23, 100301	5
438	F-sodium fluoride positron emission tomography may help determine better treatment for thigh pain after hip arthroplasty-A case report. 2020 , 8, 1651-1658	1
437	Ostôporose masculine. 2020 , 1, 466-473	
436	Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates. <i>New England Journal of Medicine</i> , 2020 , 383, 2188	2
435	Diaphyseal femoral fracture due to severe vitamin D deficiency and low parathyroid hormone levels on long-term hemodialysis: a case report. 2020 , 15, 179	0
434	Screening to identify signals of opioid drug interactions leading to unintentional traumatic injury. 2020 , 130, 110531	6
433	Osteoporosis Therapeutics 2020. 2020 , 262, 397-422	6
432	Atypical ulnar fracture with atypical femoral fracture: A case report and literature review. 2020,	2
431	Clinical outcomes of using contralateral-side laterally bent intramedullary nails in atypical femur fractures with femoral bowing. 2021 , 141, 1291-1296	5
430	Atypical femur fractures: current understanding and approach to management. 2020 , 12, 1759720X20916983	4
429	Unique Form of Atypical Subtrochanteric Femoral Fracture at the Medial Cortex: A Report of 3 Cases. 2020 , 10, e1900545	1
428	Bilateral subtrochanteric insufficiency fracture following mini-gastric bypass. A case report. 2020 , 6, 32	
427	Isoliquiritigenin Derivatives Inhibit RANKL-Induced Osteoclastogenesis by Regulating p38 and NF- B Activation in RAW 264.7 Cells. 2020 , 25,	7
426	Atypical periprosthetic femoral fracture associated with long-term bisphosphonate therapy. 2020 , 15, 414	5

Intermittent Parathyroid Hormone Accelerates Stress Fracture Healing More Effectively Following Cessation of Bisphosphonate Treatment. **2020**, 4, e10387

424	Optimizing DXA to Assess Skeletal Health: Key Concepts for Clinicians. 2020 , 105,	2
423	Intramedullary Nail Fixation with Autologous Bone Marrow Transplantation in an Incomplete Atypical Femoral Fracture Patient: Use of Bone Marrow Extracted from the Hollow Reamer. 2020 , 2020, 2878651	1
422	Bilateral atypical ulnar fractures occurring after long-term treatment with bisphosphonate for 7 years and with teriparatide for 2 years: a case report. 2020 , 31, 2473-2476	1
421	Is Femoral Fracture Healing Really Compromised in Patients with Rheumatoid Arthritis? Comparison Study Between Rheumatoid and Non-rheumatoid Arthritis Patients. 2020 , 54, 599-607	
420	Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates. <i>New England Journal of Medicine</i> , 2020 , 383, 743-753	70
419	Revision osteosynthesis after primary treatment of atypical ulnar fractures associated with bisphosphonate usage - Nonunion after ordinary open reduction and internal fixation. 2021 , 141, 1855-1862	2
418	Atypical periprosthetic femoral fractures of the hip: characterisation of three cases. 2020 , 30, 77-85	3
417	Reduced cortical bone thickness increases stress and strain in the female femoral diaphysis analyzed by a CT-based finite element method: Implications for the anatomical background of fatigue fracture of the femur. 2020 , 13, 100733	3
416	Risk of complete atypical femur fracture with Oral bisphosphonate exposure beyond three years. 2020 , 21, 801	1
415	Pharmacologic management of metastatic bone disease. 2020 , 115735	1
414	The Influence of Demographic Factors on the Location of Bisphosphonate-related Atypical Femoral Fractures. 2020 , 54, 116-120	1
413	Duration of Bisphosphonate Drug Holidays and Associated Fracture Risk. 2020 , 58, 419-426	18
412	Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition. 2020 , 34, e125-e141	6
411	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE. 2020 , 26, 1-46	164
410	Biological activity is not suppressed in mid-shaft stress fracture of the bowed femoral shaft unlike in "typical" atypical subtrochanteric femoral fracture: A proposed theory of atypical femoral fracture subtypes. 2020 , 137, 115453	13
409	Proanthocyanidin-rich grape seed extract improves bone loss, bone healing, and implant osseointegration in ovariectomized animals. 2020 , 10, 8812	4
408	Zoledronic Acid Substantially Improves Bone Microarchitecture and Biomechanical Properties After Rotator Cuff Repair in a Rodent Chronic Defect Model. 2020 , 48, 2151-2160	9

(2020-2020)

407	Multiple ipsilateral femoral stress fractures in a patient taking denosumab for osteoporosis-a case report. 2020 , 31, 2263-2267	1
406	Osteoporosis and Spine Surgery: A Critical Analysis Review. 2020 , 8, e0160	1
405	Hypophosphatasia in adolescents and adults: overview of diagnosis and treatment. 2020, 31, 1445-1460	14
404	The limitations of today's clinical guidance: Atypical femoral fracture and long-term bone-modifying agents in the oncology setting. 2020 , 26, 1180-1189	O
403	The Epidemiology of Metatarsal Fractures Among Older Females With Bisphosphonate Exposure. 2020 , 59, 269-273	
402	Updates in epidemiology, pathophysiology and management strategies of glucocorticoid-induced osteoporosis. 2020 , 15, 283-298	9
401	Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. 2020 , 26, 1784-1802	5
400	Fifty years of bisphosphonates: What are their mechanical effects on bone?. 2020, 138, 115518	5
399	Niclosamide and its derivative DK-520 inhibit RANKL-induced osteoclastogenesis. 2020 , 10, 1685-1697	1
398	Regulation of Osteoclast Differentiation at Multiple Stages by Protein Kinase D Family Kinases. 2020 , 21,	4
397	Atypical femoral fracture with bisphosphonate use. 2020 , 113, 825-826	
396	A retrospective database study of oral corticosteroid and bisphosphonate prescribing patterns in England. 2020 , 30, 5	4
395	[Special aspects of stress fractures]. 2020 , 60, 506-513	1
394	Favorable skeletal benefit/risk of long-term denosumab therapy: A virtual-twin analysis of fractures prevented relative to skeletal safety events observed. 2020 , 134, 115287	6
393	Impending Atypical Femur Fracture Presenting as Painful Total Knee Arthroplasty: A Report of 2 Cases. 2020 , 10, e0160	2
392	Biodegradable Magnesium-Based Implants in Orthopedics-A General Review and Perspectives. 2020 , 7, 1902443	105
391	Replacing one evil with another: Is the fibula really a dispensable spare part available for transfer in patients with medication-related osteonecrosis of the jaws?. 2020 , 129, e257-e263	2
390	Increased rate of reoperation in atypical femoral fractures is related to patient characteristics and not fracture type. A nationwide cohort study. 2020 , 31, 951-959	5

389	Combination and sequential treatment in women with postmenopausal osteoporosis. 2020, 21, 477-490	18
388	Adult hypophosphatasia with a novel mutation: Report of an Indian kindred. 2020 , 12, 100247	2
387	The biology and treatment of acute long-bones diaphyseal fractures: Overview of the current options for bone healing enhancement. 2020 , 12, 100249	18
386	Assessment of the multifactorial causes of atypical femoral fractures using a novel multiscale finite element approach. 2020 , 135, 115318	8
385	Asian ethnicity is associated with atypical femur fractures in an Australian population study. 2020 , 135, 115319	9
384	Bone Mineral Densitometry Reporting: Pearls and Pitfalls. 2021 , 72, 490-504	1
383	Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. 2020 , 16, 437-447	78
382	Drugs for the Skinternist. 2021 , 430-444.e3	
381	Evaluation of factors affecting the occurrence of second atypical fracture after bone union of the first atypical fracture. 2021 , 143, 115671	0
380	Outcome of revision surgery for bisphosphonate related subtrochanteric fracture non-union following failed intramedullary nailing. <i>Injury</i> , 2021 , 52, 582-588	6
379	RANKL as a target for the treatment of osteoporosis. 2021 , 39, 91-105	13
378	Benign Osseous Tumors and Tumor-Like Conditions. 2021 , 42, 150-163	O
377	Trends in hip and distal femoral fracture rates in Italy from 2007 to 2017. 2021, 142, 115752	4
376	Bisphosphonates pharmacology and use in the treatment of osteoporosis. 2021 , 1721-1736	1
375	Osteoporosis Diagnosis and Management. 2021 , 6, 111-133	
374	miRNAs in osteoclast biology. 2021 , 143, 115757	3
374	miRNAs in osteoclast biology. 2021 , 143, 115757 The safety profile of denosumab in oncology beyond the safety of denosumab as an anti-osteoporotic agent: still more to learn. 2021 , 20, 191-213	3

(2021-2021)

371	Denosumab induced atypical fracture of free vascularized fibular graft 20 years after tumour reconstruction. 2021 , 91, E335-E337	
370	Cumulative incidence of femoral localized periosteal thickening (beaking) preceding atypical femoral fractures in patients with rheumatoid arthritis. 2021 , 32, 363-375	2
369	Bone Metabolism. 2021 , 523-538	
368	Condition still critical: compliance and persistence with osteoporosis medications. 2021 , 1695-1707	
367	Fracture rates in patients discontinuing alendronate treatment in real life: a population-based cohort study. 2021 , 32, 1103-1115	3
366	On the evolution and contemporary roles of bone remodeling. 2021 , 727-772	1
365	The Effect of Teriparatide on the Hip: A Literature Review. 2021 , 33, 45-52	1
364	Two cases of atypical femoral fracture in cancer patients administered with bone-modifying agents. 2021 , 16, 170-173	
363	Behandlung osteoporotischer Frakturen. 2021 , 275-295	
362	Bisphosphonate: An Invaluable Medication or Abandoned Acid?. 2021 , 34, 122	
362 361	Bisphosphonate: An Invaluable Medication or Abandoned Acid?. 2021, 34, 122 Management of bone health in men with prostate cancer. 2021, 1407-1419	
361	Management of bone health in men with prostate cancer. 2021 , 1407-1419	0
361 360	Management of bone health in men with prostate cancer. 2021 , 1407-1419 Vertebral fracture identification. 2021 , 1511-1533 Metabolic activities affect femur and lumbar vertebrae remodeling, and anti-resorptive risedronate	0
361 360 359	Management of bone health in men with prostate cancer. 2021, 1407-1419 Vertebral fracture identification. 2021, 1511-1533 Metabolic activities affect femur and lumbar vertebrae remodeling, and anti-resorptive risedronate disturbs femoral cortical bone remodeling. 2021, 53, 103-114 Don't Forget to "Own the Bone": Commentary on an article by Kyung-Jae Lee, MD, et al.: "Progression of Asymptomatic Contralateral Femur in Patients with Complete Atypical Femoral	0
361 360 359 358	Management of bone health in men with prostate cancer. 2021, 1407-1419 Vertebral fracture identification. 2021, 1511-1533 Metabolic activities affect femur and lumbar vertebrae remodeling, and anti-resorptive risedronate disturbs femoral cortical bone remodeling. 2021, 53, 103-114 Don't Forget to "Own the Bone": Commentary on an article by Kyung-Jae Lee, MD, et al.: "Progression of Asymptomatic Contralateral Femur in Patients with Complete Atypical Femoral Fracture, According to Initial Radiographic Findings". 2021, 103, e6	
361 360 359 358 357	Management of bone health in men with prostate cancer. 2021, 1407-1419 Vertebral fracture identification. 2021, 1511-1533 Metabolic activities affect femur and lumbar vertebrae remodeling, and anti-resorptive risedronate disturbs femoral cortical bone remodeling. 2021, 53, 103-114 Don't Forget to "Own the Bone": Commentary on an article by Kyung-Jae Lee, MD, et al.: "Progression of Asymptomatic Contralateral Femur in Patients with Complete Atypical Femoral Fracture, According to Initial Radiographic Findings". 2021, 103, e6 Therapies for Preventing Bone Loss with Glucocorticoid Treatment. 2021, 19, 34-39 Bisphosphonate-related atypical insufficiency fracture of the tibial plateau: A case report. 2021,	2

353 Long-term bisphosphonate treatment: continuation and interruption. **2021**, 1805-1825

352	Osteoporosis in childhood and adolescence. 2021 , 911-950		O
351	Population-based, three-dimensional analysis of age- and sex-related femur shaft geometry differences. 2021 , 32, 1631-1638		3
350	Scope and Limits of Teriparatide Use in Delayed and Nonunions: A Case Series. 2021 , 11, 47-57		2
349	Evaluation and management of atypical femoral fractures: an update of current knowledge. 2021 , 31, 825-840		О
348	Deep neural networks with promising diagnostic accuracy for the classification of atypical femoral fractures. 2021 , 92, 394-400		2
347	Nano-Based Biomaterials as Drug Delivery Systems Against Osteoporosis: A Systematic Review of Preclinical and Clinical Evidence. 2021 , 11,		14
346	Morphological divergence in the curvature of human femoral diaphyses: Tracing the central mass distributions of cross-sections. 2021 , 239, 46-58		O
345	Bisphosphonate Drug Holidays in Primary Care: When and What to Do Next?. 2021 , 19, 182-188		4
344	Valgus osteotomy for atypical interprosthetic femoral fracture with lateral bowing of the femur. 2021 , 31, 100381		1
343	Duration-Dependent Increase of Human Bone Matrix Mineralization in Long-Term Bisphosphonate Users with Atypical Femur Fracture. <i>Journal of Bone and Mineral Research</i> , 2021 , 36, 1031-1041	6.3	3
342	Bisphosphonate holidays. 2021 , 59, 35-36		1
341	Subtrochanteric femur fractures: current review of management. 2021 , 6, 145-151		3
340	The Sydney AFF Score: A Simple Tool to Distinguish Females Presenting With Atypical Femur Fractures Versus Typical Femur Fractures. <i>Journal of Bone and Mineral Research</i> , 2021 , 36, 910-920	6.3	2
339	The Genetics of Atypical Femur Fractures-a Systematic Review. 2021 , 19, 123-130		4
338	Adverse events associated with bone-directed therapies in patients with cancer. 2021 , 115901		3
337	Fraturas atpicas do fmur associadas ao uso crílico de bisfosfonatos: Uma stie de casos de 66 pacientes.		
336	Intra-operative Clodronate Rinsing Improves the Integration of the Femoral Stem in a Prospective, Double-blinded, Randomized, Placebo-controlled Clinical RSA-study. 2021 , 15, 1-12		

335 Atipik Femur KEEOlan Hastalar BKarl Femurda Lakomplet KER Varl BB De Brlendirilmesi.

334	The treatment gap: The missed opportunities for osteoporosis therapy. 2021 , 144, 115833		5
333	A Bisphosphonate With a Low Hydroxyapatite Binding Affinity Prevents Bone Loss in Mice After Ovariectomy and Reverses Rapidly With Treatment Cessation. 2021 , 5, e10476		2
332	Testosterone therapy and bone quality in men with diabetes and hypogonadism: Study design and protocol. 2021 , 21, 100723		1
331	Duration of Bisphosphonate Drug Holidays in Osteoporosis Patients: A Narrative Review of the Evidence and Considerations for Decision-Making. 2021 , 10,		8
330	Is open bone graft always necessary when treating aseptic subtrochanteric nonunion with a reamed intramedullary nail?. 2021 , 22, 145		3
329	Histopathological Finding of Microdamage Accumulation in Atypical Subtrochanteric Femoral Fracture. 2021 , 2021, 6624414		
328	Intractable Fractures of the Bilateral Proximal Ulnae After 8 Years of Zoledronate Treatment for Breast Cancer Bone Metastasis. 2021 ,		5
327	Subtrochanteric atypical femoral fracture induced solely by glucocorticoid without bisphosphonate treatment: a case report. 2021 , 32, 2115-2118		0
326	Incidence of Hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal Women With Osteoporosis in the Phase 3 Long-Term Odanacatib Fracture Trial. <i>Journal of Bone and Mineral Research</i> , 2021 , 36, 1225-1234	6.3	2
325	Atypical periprosthetic femur fracture on an underestimated atypical femoral pattern. A case report. 2021 , 32, 100407		1
324	Differences in subtrochanteric and diaphyseal atypical femoral fractures in a super-aging prefectural area: YamaCAFe Study. 2021 , 39, 700-711		
323	Progression of atypical femur stress fracture after discontinuation of bisphosphonate therapy. 2021 , 32, 2119-2123		1
322	Effects of treatment with a bone-targeted prostaglandin E2 receptor 4 agonist C3 (Mes-1007) in a mouse model of severe osteogenesis imperfecta. 2021 , 145, 115867		O
321	Evaluation of the Nature and Etiologies of Risk Factors for Diaphyseal Atypical Femoral Fractures. 2021 , 30, 430-436		0
320	Peri-implant atypical femoral fracture after nail or plate osteosynthesis. 2021,		2
319	Recommandations fran\(\text{Bises}\) de la prise en charge et du traitement de l\(\text{Bist}\)porose masculine. 2021 , 88, 173-182		0
318	Practical Guidance for Prevention and Management of Glucocorticoid-Induced Osteoporosis for the Allergist/Immunologist. 2021 , 9, 1841-1850		1

317	Stress Fracture of the Femoral Shaft in Paget's Disease of Bone: A Case Report. 2021 , 28, 171-178	O
316	Atraumatic fractures of the femur. 2021 , 94, 20201457	1
315	WNT7B overexpression rescues bone loss caused by glucocorticoids in mice. 2021 , 35, e21683	O
314	Periprosthetic Atypical Femoral Fractures Exist: A Retrospective Study at a Single Institution. Prevalence on 115 Periprosthetic Femoral Fractures Around a Primary Hip Stem. 2021 , 36, 2189-2196	6
313	Update on Rare Adverse Events from Osteoporosis Therapy and Bisphosphonate Drug Holidays. 2021 , 50, 193-203	5
312	Disturbance of osteonal bone remodeling and high tensile stresses on the lateral cortex in atypical femoral fracture after long-term treatment with Risedronate and Alfacalcidol for osteoporosis. 2021 , 14, 101091	4
311	Long-Term Treatment of Postmenopausal Osteoporosis. 2021 , 36, 544-552	1
310	Incidence of Atypical Femoral Fracture and Its Mortality in a Single Center in Singapore. 2021 , 5, e10515	1
309	Analysis of the subsequent treatment of osteoporosis by transitioning from bisphosphonates to denosumab, using quantitative computed tomography: A prospective cohort study. 2021 , 14, 101090	2
308	Bisphosphonate treatment and the risk of atypical femoral fracture among patients participating in a Fracture Liaison Service of a tertiary medical center. 2021 , 16, 86	O
307	Patchouli Alcohol Modulates the Pregnancy X Receptor/Toll-like Receptor 4/Nuclear Factor Kappa B Axis to Suppress Osteoclastogenesis. 2021 , 12, 684976	0
306	Osteoporosis in older people. 2021 , 51, 265-274	1
305	Osteoporosis: A silent disease fraught with fragility fractures in geriatric population. 2021, 8, 7-14	
304	Critical Issues in Osteoporosis Management. 2021 , 37-50	
303	Atypical periprosthetic femoral fractures after arthroplasty for fracture are at high risk of complications. 2021 , 11, 14378	1
302	The importance of reconstruction nailing for diaphyseal atypical femoral fractures: a comparative study with standard nailing. 2021 , 1	O
301	Bisphosphonate use in children with cerebral palsy. 2021 , 7, CD012756	2
300	Functional Analyses of Four Missense Mutations Present in Patients with Atypical Femoral Fractures. 2021 , 22,	1

299	The Treatment Gap in Osteoporosis. 2021 , 10,		4
298	Rethinking of osteoporosis through a sex- and gender-informed approach in the COVID-19 era. 2021 ,		1
297	The relationships between structural organization, material properties, and loading conditions and the risk of fracture and fracture location in the femur.		
296	Lower trabecular bone score is associated with an increased incidence of localized femoral periosteal thickening. 2021 , 39, 952-961		O
295	Targeting Drug Delivery in the Elderly: Are Nanoparticles an Option for Treating Osteoporosis?. 2021 , 22,		1
294	Atypical periprosthetic femoral fractures of the hip: A PRISMA compliant systematic review. <i>Injury</i> , 2021 , 52, 2407-2414	2.5	4
293	New Insights Into Osteoclast Biology. 2021 , 5, e10539		7
292	Secondary Subtrochanteric Fracture After Atypical Femoral Shaft Fracture Treated With Intramedullary Nail. 2021 , 13, e17544		
291	Current concepts in the management of bisphosphonate associated atypical femoral fractures. 2021 , 12, 660-671		1
290	Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society. 2021 , 28, 973-997		18
289	Diagnostic Criteria and Treatment of Atypical Ulnar Fractures Associated With Prolonged Bisphosphonate Therapy: Multicenter Case Analysis. 2021 ,		2
288	Health-related quality of life outcomes after surgical treatment of atypical femur fractures: a multicenter retrospective cohort study. 2021 , 5, e10514		
287	Straight nail insertion through a laterally shifted entry for diaphyseal atypical femoral fractures with bowing: good indications and limitations of this technique. 2021 , 45, 3223-3232		2
286	Differentiating the causes of adynamic bone in advanced chronic kidney disease informs osteoporosis treatment. 2021 , 100, 546-558		10
285	Bilateral atypical fractures of the femur: Ten years AFTER ten years of bisphosphonate therapy. 2021 , 15, 101112		1
284	Biomechanical mechanisms of atypical femoral fracture. 2021 , 124, 104803		1
283	Evaluation of the osteoporosis patient. 2021 , 1475-1500		2
282	A Novel Surgical Method for Treating Symptomatic Incomplete Atypical Femoral Fracture using Percutaneous Elastic Intramedullary Nailing. 2021 , 12, 21514593211015104		О

²⁸¹ Impact of a Bisphosphonate Drug Holiday on the Bone Mineral Density in Patients with Osteoporosis. **2021**, 3, 101

280	Osteoporosis treatment rate following hip fracture in a community hospital. 2021 , 16, 8	4
279	Clinical Outcomes and Radiologic Characteristics of Insufficiency Femoral Neck Fracture in Elderly Patients. 2021 , 34, 1	
278	Once-weekly parathyroid hormone combined with ongoing long-term alendronate treatment promotes osteoporotic fracture healing in ovariectomized rats. 2021 , 39, 2103-2115	3
277	Stress Fractures of the Femur. 2015 , 111-124	5
276	Factors Contributing to Atypical Femoral Fractures. 2016 , 125-136	1
275	Osteoporosis in Primary Hyperparathyroidism: Considerations for Diagnosis and Treatment. 2017 , 343-358	1
274	Combination and Sequential Osteoanabolic/Antiresorptive Therapy in Osteoporosis Treatment. 2020 , 363-374	1
273	Osteoporosis in Men. 2020 , 391-406	1
272	Basic Aspects of Bone Mineralization. 2020 , 89-113	1
271	Emerging Orthobiologic Approach to Fractures. 2017 , 473-478	1
270	Medical and Metabolic Considerations in Athletes With Stress Fractures. 2020 , 30-94	1
269	Bisphosphonate drug holidays: Risk of fractures and mortality in a prospective cohort study. 2020 , 138, 115431	2
268	Location of atypical femoral fracture can be determined by tensile stress distribution influenced by femoral bowing and neck-shaft angle: a CT-based nonlinear finite element analysis model for the 2.5 assessment of femoral shaft loading stress. <i>Injury</i> , 2017 , 48, 2736-2743	31
267	Atypical diaphyseal femoral fractures: Considerations on surgical technique. <i>Injury</i> , 2019 , 50 Suppl 2, S65-S69	6
266	Treatment options for glucocorticoid-induced osteoporosis. 2020 , 21, 721-732	13
265	Bone Health and Osteoporosis Prevention and Treatment. 2020 , 63, 770-787	1
264	Does Teriparatide Improve Fracture Union?: A Systematic Review. 2020 , 27, 167-174	4

(2021-2015)

263	Bilateral atypical femoral subtrochanteric fractures in a premenopausal patient receiving prolonged bisphosphonate therapy: evidence of severely suppressed bone turnover. 2015 , 12, 273-7	8
262	Histological study of atraumatic periprosthetic fractures: does atypical periprosthetic fracture exist?. 2017 , 14, 136-139	13
261	Adult-onset hypophosphatasia diagnosed following bilateral atypical femoral fractures in a 55-year-old woman. 2017 , 14, 347-353	7
260	The first reported case of Atypical Femoral Fracture caused by daily ibandronate prescribed for bone metastases in breast cancer. 2017 , 2017,	3
259	Management of atypical femoral fracture in a patient with osteogenesis imperfecta. 2017, 2017,	4
258	Low-energy atypical femoral shaft and ipsilateral neck fracture: a rare association. 2017, 2017,	2
257	Analysis of the Changes in Femoral Varus Bowing and the Factors Affecting Nonunion for the Treatment of Femoral Shaft Fractures over 60 Years Old Using Piriformis Fossa Insertion Intramedullary Nailing. 2020 , 33, 65	1
256	Long-term bisphosphonate treatment coupled with ovariectomy in mice provokes deleterious effects on femoral neck fracture pattern and modifies tibial shape. 2020 , 1, 512-519	3
255	Effects of combination treatment with alendronate and raloxifene on skeletal properties in a beagle dog model. 2017 , 12, e0181750	4
254	Atypical femoral fractures and biphosphonates. 2017 , 38, 872	1
253	Osteonecrosis of the Jaw and Bilateral Atypical Femoral Fracture Both Occurring During Treatment for Osteoporosis: A Case Report. 2018 , 33, 194-198	3
252	[Clinical heterogeneity of atypical fractures during prolonged use of bisphosphonatesrisk factors and bone turnover markers]. 2014 , 58, 855-61	1
251	Controversies in the treatment of postmenopausal osteoporosis: How long to treat with bisphosphonates?. 2020 , 64, 331-336	3
250	Magnetic resonance imaging findings in the hyperacute phase of atypical femoral fracture: a case description. 2020 , 10, 2366-2369	1
249	Progression of Asymptomatic Contralateral Femur in Patients with Complete Atypical Femoral Fracture, According to Initial Radiographic Findings. 2021 , 103, 123-130	3
248	Atypical Subtrochanteric Femur Fracture and Hip Osteoarthritis Treated with a Revision Monoblock Stem and Strut Allograft: A Case Report. 2020 , 10, e2000038	1
247	Bilateral Atypical Femur Fractures Complicated by Carbon Fiber Cephalomedullary Nail Fracture: A Case Report. 2020 , 10, e2000182	0
246	Molecular Signaling Pathways and Essential Metabolic Elements in Bone Remodeling: An Implication of Therapeutic Targets for Bone Diseases. 2021 , 22, 77-104	2

245	Proximal femoral insufficiency fracture after interlocking intramedullary nailing for atypical femoral fracture. 2020 , 71,	1
244	Hypophosphatasia: Biological and Clinical Aspects, Avenues for Therapy. 2020 , 41, 13-27	16
243	Validation Study of Claims-based Definitions of Suspected Atypical Femoral Fractures Using Clinical Information. 2016 , 21, 13-19	7
242	Caveats of bisphosphonate abuse. 2016 , 50, 434-9	2
241	Osteoporosis Treatment: When to Discontinue and When to Re-start. 2013 , 1, 323-35	12
240	Suitability and limitations of mesenchymal stem cells to elucidate human bone illness. 2019 , 11, 578-593	7
239	Atypical Femur Fractures in Patients Treated with Bisphosphonates: Identification, Management, and Prevention. 2016 , 7,	6
238	Atypical femoral neck stress fracture in a human immunodeficiency virus-infected patient despite anti-osteoporotic treatment: A case report. 2020 , 66, 364-367	O
237	Denosumab and Atypical Femoral Fractures: A Scoping Literature Review. 2017 , 23,	O
236	Can bone turnover markers help to define the suitability and duration of bisphosphonate drug holidays?. 2020 , 9,	4
235	Paradoxical Stress Fracture in a Patient With Multiple Myeloma and Bisphosphonate Use. 2020 , 12, e9837	1
234	Rheumatoid arthritis and bone health. 2020 , 20, 565-567	4
233	Current concept of stress fractures with an additional category of atypical fractures: a perspective review with representative images. 2021 , 12, 20420188211049619	O
232	Treatment of Glucocorticoid-Induced Osteoporosis and Risk Factors for New Vertebral Fractures in Female Patients with Autoimmune Diseases. 2021 , 2021, 5515653	
231	Proceedings of the 2021 Santa Fe Bone Symposium: Advances in the Management of Osteoporosis and Metabolic Bone Diseases. 2021 , 25, 3-3	1
230	Fracture Risk Following an Atypical Femoral Fracture. <i>Journal of Bone and Mineral Research</i> , 2021 , 6.3	1
229	Risk of subtrochanteric and femoral shaft fractures due to bisphosphonate therapy in asthma: a population-based nested case-control study. 2021 , 1	0
228	ICA treatment diabets induced bone loss via primary cilia/Gli2/Osteocalcin signaling pathway.	

227	Duration of Bisphosphonate Treatment. 2014 , 87, 151	
226	Customized Treatment for the Prevention of Osteoporotic Fracture. 2014 , 21, 194	
225	Bisphosphonates for Osteoporosis. 2015 , 345-371	1
224	An atypical fracture in male patient with osteogenesis imperfecta. 2015 , 12, 278-81	19
223	Osteoporosis and Hip Fractures. 2015 , 141-158	
222	Applying low-intensity pulsed ultrasounds (LIPUS) to a zoledronate-associated atypical femoral shaft fracture without cessation of zoledronate therapy for 3 years follow up: a case report. 2015 , 12, 269-72	5
221	Recurrent Vertebral Compression Fracture while on Bisphosphonate Therapy IWhat is the Next Best Step in Management?. 2015 , 2, 18-22	
220	Epidemiology of Atypical Subtrochanteric and Femoral Shaft Fractures. 2016 , 95-106	
219	Surgical or nonsurgical treatment of osteoporotic fractures. 2016 , 59, 857	3
218	Fracture Care in the Elderly. 2016 , 243-264	
218	Fracture Care in the Elderly. 2016 , 243-264 Treatment of Osteoporosis in Long-Term Care. 2016 , 229-241	
		1
217	Treatment of Osteoporosis in Long-Term Care. 2016 , 229-241 Effects of Teriparatide Administration on Fracture Healing after Intramedullary Nailing in Atypical	1
217	Treatment of Osteoporosis in Long-Term Care. 2016 , 229-241 Effects of Teriparatide Administration on Fracture Healing after Intramedullary Nailing in Atypical Femoral Fractures. 2016 , 51, 231	1
217 216 215	Treatment of Osteoporosis in Long-Term Care. 2016, 229-241 Effects of Teriparatide Administration on Fracture Healing after Intramedullary Nailing in Atypical Femoral Fractures. 2016, 51, 231 The Geometry of Lower Extremity and Atypical Femoral Fractures. 2016, 103-134	1
217 216 215	Treatment of Osteoporosis in Long-Term Care. 2016, 229-241 Effects of Teriparatide Administration on Fracture Healing after Intramedullary Nailing in Atypical Femoral Fractures. 2016, 51, 231 The Geometry of Lower Extremity and Atypical Femoral Fractures. 2016, 103-134 "Atypical" atypical femur fractures and use of bisphosphonates. 2016, 13, 204-208	6
217 216 215 214 213	Treatment of Osteoporosis in Long-Term Care. 2016, 229-241 Effects of Teriparatide Administration on Fracture Healing after Intramedullary Nailing in Atypical Femoral Fractures. 2016, 51, 231 The Geometry of Lower Extremity and Atypical Femoral Fractures. 2016, 103-134 "Atypical" atypical femur fractures and use of bisphosphonates. 2016, 13, 204-208 Verfiderungen im Knochenstoffwechsel und/oder an der Knochenmatrix. 2016, 207-295	6

209	PhysiciansIknowledge and attitude regarding bisphosphonates-related adverse events: An observational study. 2017 , 7, 1	
208	Subtrochanteric femoral stress fracture with features of atypical femoral fracture in patient with Paget's disease: a case report. 2017 , 14, 368-371	
207	Bone Mineral Densitometry Pitfalls. 2017 , 893-923	1
206	. 2017 , 106, 421-427	
205	Simultaneous Bilateral Atypical Femoral Fracture: Case Presentation. 2017, 9,	
204	Healthy Bones After Menopause: What Has to Be Done?. 2018 , 165-186	
203	???????????????????????. 2018 , 67, 788-792	
202	Application and development of low-level laser therapy (LLLT) for osteoporosis. 2018,	
201	General Consideration and Workup of Periprosthetic Fractures. 2019, 3-18	
200	Gelenk- und Muskelschmerzen. 2019 , 1-27	
199	Gelenk- und Muskelschmerzen. 2019 , 347-373	
198	Radiologic and Serologic Factors Associated with Bone Union at Femoral Atypical Fracture. 2019 , 32, 27	1
197	Bone Health in Patients with Breast Cancer. 2019 , 15, 16	1
196	Osteoporosis. 2019 , 1-13	
195	Hip Fracture. 2019 , 1-11	
194	Lessons Learned from Long-Term Management of Hip Fracture in Patients with Osteopetrosis: A Report of Nine Hips in Five Patients. 2019 , 26, 201-206	1
193	Failure of Intramedullary Nailing for Subtrochanteric Atypical Femoral Fractures Caused by Endosteal Cortical Thickening. 2019 , 32, 211	О
192	Surgical Fixation of Atypical Femur Fractures in Bisphosphonate-treated Patients. 2019, 11, e4690	1

LED device effectively increases serum levels of 25(OH)D3 in osteoporosis rats. 2019, 191 PHARMACOLOGICAL MANAGEMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN: THE 190 CURRENT STATE OF THE ART. 2019, 26, e19-e35 Atypical femoral fracture. 189 Hip fractures following intramedullary nailing fixation for femoral fractures. Injury, 2021, 188 2.5 Infographic: Mid-term outcomes after the surgical treatment of atypical femoral fractures: 187 minimum three-year follow-up. 2021, 103-B, 1646-1647 Mid-term outcomes after the surgical treatment of atypical femoral fractures: minimum three-year 186 \circ follow-up. 2021, 103-B, 1648-1655 Open Reduction and Internal Fixation of Simultaneous, Bilateral, Atypical Femoral Shaft Fractures 185 After Nine Years of Bisphosphonate Treatment. **2021**, 13, e19177 Bisphosphonates: Mechanisms of Action and Role in Osteoporosis Therapy. 2020, 277-307 184 Post-operative Rehabilitation of Atypical Femoral Fracture in a Single Center. 2020, 5, 20200007 183 Three-Dimensional Analysis of the Morphological Features in the Femur of Atypical Fracture and 182 Practical Implications of Intramedullary Nailing. 2020, 33, 87 Bisphosphonate use and the risk of atypical fractures. 2020, 325, 1259-1262 181 180 Hip Fracture. 2020, 1161-1171 Bone Metabolism. 2020, 1-17 179 Hip and Subtrochanteric or Femoral Shaft Fractures after Bisphosphonate Use in Korean Women, 178 Using Korean National Sample Cohort. 2020, 35, e193 Evaluation and Medical Management of Vertebral Osteoporosis: Preventing the Next Fracture. 177 2020, 31-47 176 Safety Considerations for Osteoporosis Therapies. 2020, 471-484 Changes in Biomaterial Properties of Bone With Disease and Treatment. 2020, 456-480 175 Atypical stress femoral shaft fracture secondary to alendronate therapy. 2020, 12, 92 174

173	Management Challenges in Atypical Femoral Fractures: A Case Report. 2020 , 24, 50-54	1
172	Adverse Effects of Antiresorptive Therapy. 2021, 135-148	
171	Femoral Bowing and Femoral Neck-Shaft Angle Evaluation Can Reduce Atypical Femoral Fractures in Osteoporotic Patients: A Scientific Report. 2020 , 12, e10771	2
170	Long term bisphosphonate therapy & atypical femoral fractures: a word of caution. 2014 , 140, 8-10	1
169	Atypical femoral fracture in a beta-thalassemia major patient with previous bisphosphonate use: case report and a review of the literature. 2016 , 16, 75-8	4
168	Long-term Bisphosphonate Therapy-induced Periprosthetic Femoral Stress Fracture in a Sliding Hip Screw Implant: A Unique Case Report. 2016 , 6, 53-56	5
167	Atypical Femoral Fractures: Implications for the Advanced Practitioner in Oncology. 2017 , 8, 395-399	
166	Atypical femur fracture in a woman with osteogenesis imperfecta and multiple myeloma. 2018 , 18, 375-381	3
165	Peri-implant Atypical Fractures Associated with Bisphosphonates: Should this Clinical Entity be Included in the Definition of Atypical Femoral Fracture? Case Report. 2018 , 8, 66-69	
164	Intramedullary Nailing: Definitive as well as Prophylactic Fixation Method in a Case of Bilateral Atypical Femoral Fractures - A Case Report. 2019 , 9, 61-64	1
163	AN 'ATYPICAL' ATYPICAL FEMORAL FRACTURE. 2019 , 88, 182-183	
162	Denosumab-Associated Peri-Implant Atypical Femur Fracture: A Case Report. 2019 , 78, 47-51	1
161	Exchange K-nailing, Augmented Plating Technique for Atypical Femur Diaphyseal Non-union, and Implant Failure - A Case Report. 2020 , 10, 5-9	
160	Surgical Treatment for Bisphosphonate-related Atypical Femoral Fracture: A Systematic Review. 2021 , 9, 283-296	
159	Atypical femoral fracture in a metastatic bone disease patient six months after discontinuation of denosumab received sequentially to previous bisphosphonate therapy - A case report. 2021 , 21, 429-433	
158	???????????????????????. 2021 , 70, 602-605	
157	?????????????????????. 2021 , 70, 606-609	
156	[Individual aspects in eldery patients with fragility fractures]. 2021 , 61, 1107-1114	O

The Role of Microdamage in Bone Mechanics and Osteoporotic Fractures. 2022, 209-220 155 Disturbance of Osteonal Remodeling in Atypical Femoral Fracture: A Short Review of Pathogenesis 154 and a Case Report: Histomorphometric Analysis of Fracture Site. 2022, 243-270 Effects of Osteoporosis Drugs: Morphological Assessment and Adverse Events. 2022, 317-338 153 Three-Dimensional Microstructural Measurement for Predicting the Risk of Osteoporotic Fracture. 152 **2022**, 129-160 Two Cases of Atypical Femoral Fractures that Developed During Chronic Administration of 151 Zoledronic Acid for Bone Metastasis from Breast Cancer. 2020, 45, 721-729 New Frontiers in Osteoporosis Management: Optimizing Sequential and Combination Therapy. 150 2022, 617-644 Osteoporosis Management: Gaps in Patients Care and Treatment. 2022, 549-574 149 Bilateral atypical femoral fractures treated with compression hip screw and intramedullary nail 148 fixation.. 2022, 37, 100601 Bisphosphonates and the risk of atypical femur fractures.. 2021, 116297 2 147 146 Imaging of Nontraumatic Musculoskeletal Conditions. 2021, 1-16 Atypical Femoral Fracture in a Patient without Bisphosphonate or Denosumab Exposure-A Case 145 Report.. 2021, 11, 21-24 Differences in femur geometry and bone markers in atypical femur fractures and the general \circ 144 population.. **2021**, 11, 24149 Precision Medicine: Pharmacogenetics and Pharmacogenomics of Osteoporosis. 2022, 575-591 143 The contribution of deleterious rare alleles in ENPP1 and osteomalacia causative genes to atypical 2 142 femoral fracture.. 2022, Surveillance of atypical femoral fractures in a nationwide fracture register.. 2022, 93, 229-233 141 Bisphosphonate treatment is associated with decreased mortality rates in patients after 140 osteoporotic vertebral fracture.. 2022, 1 Atypical Femur Fractures. 2022, 715-734 139 Glucocorticoids and Musculoskeletal Health. 2022, 827-856 138

137	Long-term safety of eldecalcitol in Japanese patients with osteoporosis: a retrospective, large-scale database study 2022 , 40, 275		0
136	Gene Network of Susceptibility to Atypical Femoral Fractures Related to Bisphosphonate Treatment 2022 , 13,		O
135	Bone Healing and Osteoporosis. 2022 , 525-545		
134	Bone Health: Basic and Applied Bone Biology. 2022 , 3-47		
133	Generalized Uncoupled Bone Remodeling Associated With Delayed Healing of Fatigue Fractures 2022 , 6, e10598		
132	Intramedullary nailing of subtrochanteric fractures in elderly patients: Comparative study of helical blade cephalomedullary nail versus reconstruction nail <i>Injury</i> , 2022 ,	2.5	O
131	Association of atypical femoral fracture location and lower limb mechanical axis: a computed tomography-based finite element analysis 2022 , 1		О
130	The effect of zoledronic acid and denosumab on the mandible and other bones: a F-NaF-PET study 2022 , 1		
129	Bilateral Atypical Femur Fractures After Denosumab in a Bisphosphonate Naive Patient: A Case Report 2022 , 1		0
128	Specifics of Surgical Management: Proximal Femur Fractures. 2022 , 237-260		
127	Incomplete Atypical Femoral Fracture Treated by Prophylactic Intramedullary Nail Fixation: A Case Series 2022 , 14, e22725		
126	Raloxifene Use After Denosumab Discontinuation Partially Attenuates Bone Loss in the Lumbar Spine in Postmenopausal Osteoporosis 2022 , 1		2
125	Prevalence of Low Serum Alkaline Phosphatase and Hypophosphatasia in Adult Patients with Atypical Femur Fractures 2022 , 1		0
124	Atypical forearm fractures associated with long-term bisphosphonate use: the perspective of hand surgeons. 2022 , 27, 1-11		
123	Metabolic Bone Diseases and New Drug Developments 2022,		0
122	Bisphosphonate therapy associated with bilateral atypical femoral fracture and delayed union 2022 , 33, 24-32		
121	Biomechanical analysis of the correlation between mid-shaft atypical femoral fracture (AFF) and axial varus deformation 2022 , 17, 165		
120	Drug therapy for osteoporosis in older adults 2022 , 399, 1080-1092		11

119	Subtrochanteric Insufficiency Fracture Occurring 5 Years after Surgery at the Steinmann Pin Insertion Site for Fracture Reduction 2022 , 58,	
118	UK clinical guideline for the prevention and treatment of osteoporosis 2022 , 17, 58	6
117	[Atypical femoral fracture : Pitfalls in surgical treatment] 2022, 1	
116	Bilateral Bisphosphonate-related Atypical Femoral Neck Fracture in a Patient with Familial Mediterranean Fever: A Case Report. 2022 , 28, 74-76	Ο
115	Vitamin D deficiency in children with cerebral palsy: A narrative review of epidemiology, contributing factors, clinical consequences and interventions 2022 , 29, 2007-2013	
114	Fracturas por sobrecarga (fracturas por fatiga y fracturas por insuficiencia Bea). 2021 , 54, 1-13	
113	Exploring the Mechanisms Underlying Drug-Induced Fractures Using the Japanese Adverse Drug Event Reporting Database 2021 , 14,	0
112	Surgical and Pharmacological Management of Periprosthetic Atypical Femoral Fractures: A Narrative Literature Review 2022 , 13, 21514593221090392	
111	Continuation of Bisphosphonate Therapy for Osteoporosis beyond 5 Years <i>New England Journal of Medicine</i> , 2022 , 386, 1467-1469	1
110	Interpretation of expert consensus on prevention and treatment of osteoporosis in perimenopausal and postmenopausal women. 2022 ,	Ο
109	Alendronate prolongs the reversal-resorption phase in human cortical bone remodeling 2022, 116419	Ο
108	When and how to stop denosumab therapy in a patient with osteoporosis 2022 ,	1
107	Intramedullary Nailing for Atypical Femoral Fracture With Lateral Bowing: Does Medial Gap Matter?. 2022 , 13, 21514593211070130	1
106	The clinician's guide to prevention and treatment of osteoporosis 2022 ,	11
105	Contemporaneous Insufficiency Fractures of Bilateral Femoral Necks in an Older Patient Taking Bisphosphonate: A Case Report and Literature Review 2022 , 2022, 9294289	
104	Bone Metastases: From Mechanisms to Treatment 2022 , 151277	O
103	Atypical fracture of the femur in a patient with postmenopausal osteoporosis after four injections of zoledronic acid. 2022 , 26, 27-32	
102	Atypical Periprosthetic Femoral Fracture Associated With Prolonged Bisphosphonate Therapy: A Two-Centered Retrospective Case Series and Literature Review 2022 , 14, e24514	

101	Management of menopause: a view towards prevention 2022,	6
100	Multiple stress fractures of unilateral femur: A case report. 2022 , 10, 4280-4287	
99	Opioid Drug-Drug-Drug Interactions and Unintentional Traumatic Injury: Screening to Detect Three-Way Drug Interaction Signals. 2022 , 13,	O
98	Guideline No. 422g: Menopause and Osteoporosis 2022 , 44, 527-536.e5	O
97	Directive clinique n 422g : Mħopause et ostòporose 2022 , 44, 537-546.e5	
96	Thiazide use and skeletal microstructure: Results from a multi-ethnic study. 2022 , 101589	
95	The crosstalk between bone remodeling and energy metabolism: A translational perspective 2022 ,	O
94	CPI Adult Cancer Imaging Special Edition Module. 2019 ,	
93	Fragility Fractures of the Acetabulum: Current Concepts for Improving Patients Dutcomes.	
92	Plate Fixation for Atypical Fractures of the Femoral Diaphysis. 2022 , 14, 178	
91	Bone regeneration: a message from clinical medicine and basic science.	
90	Skeletal Aging. 2022, 97, 1194-1208	2
89	Bilateral Incomplete Atypical Femur Fractures with Severe Bowing Treated Using Elastic Intramedullary Nails. 2022 , 12,	O
89 88		0
	Intramedullary Nails. 2022, 12, Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Adults: Consensus	
88	Intramedullary Nails. 2022, 12, Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Adults: Consensus Recommendations From the Belgian Bone Club. 13,	
88 8 ₇	Intramedullary Nails. 2022, 12, Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Adults: Consensus Recommendations From the Belgian Bone Club. 13, MicroRNA-27a is essential for bone remodeling by modulating p62-mediated osteoclast signaling.	

83	Characteristics of bisphosphonate and non-bisphosphonate related atypical femoral fracture in a South East Asian population Becondary analysis. 2022 , 162, 116455		
82	Bilateral atypical femoral fracture related to bisphosphonate therapy. 2022 , 66-66		
81	Imaging of Nontraumatic Musculoskeletal Conditions. 2022 , 689-703		
80	Is it time to consider population screening for fracture risk in postmenopausal women? A position paper from the International Osteoporosis Foundation Epidemiology/Quality of Life Working Group. 2022 , 17,		1
79	Whole Exome Sequencing in Two Southeast Asian Families With Atypical Femur Fractures.		0
78	Rechallenge of denosumab in advanced giant cell tumor of the bone after atypical femur fracture: A case report and review of literature. <i>Frontiers in Oncology</i> , 12,	5.3	O
77	Musculoskeletal Injuries. 2022 , 440-456		
76	Medium-Term Outcomes of a Forward-Striking Technique to Reduce Fracture Gaps during Long Cephalomedullary Nailing in Subtrochanteric Femoral Fractures. <i>Injury</i> , 2022 ,	2.5	О
75	Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults. <i>New England Journal of Medicine</i> , 2022 , 387, 299-309	59.2	6
74	Atypical femur fractures associated with bisphosphonate therapy: post-operative outcomes.		1
73	Bisphosphonate Drug Holiday and Fracture Risk: Reviewing the Evidence. 2022 , 8, 37-55		
72	Change in Bone Mineral Density in Stroke Patients with Osteoporosis or Osteopenia. 2022 , 19, 8954		
71	Osteoporosis: An Update on Screening, Diagnosis, Evaluation, and Treatment. 1-7		
70	Effects of a Whole Plant Extract of Scutellaria rubropunctata var. rubropunctata on Bone Metabolism with Estrogen Receptor Activation. 2022 , 11, 2075		
69	Exploring the effect of the quaternary regulation[theory of peripheral nerve-angiogenesis-osteoclast-osteogenesis[bn osteoporosis based on neuropeptides. 13,		1
68	Atypische femurfracturen: overzicht van de epidemiologie en de behandeling aan de hand van een casus.		
67	Impairment of APPL1/Myoferlin facilitates adipogenic differentiation of mesenchymal stem cells by blocking autophagy flux in osteoporosis. 2022 , 79,		
66	Bisphosphonate-induced atypical femoral fracture in tandem: long-term follow-up is warranted. 2022 , 2022,		O

65	Endocrine assessment, chemotherapy, nonsurgical treatment, and rehabilitation for osteoporotic spine fractures: WFNS spine committee recommendations. 2022 , 66,	O
64	Integration of pharmacodynamics and metabolomics reveals the therapeutic effects of 6-acetylacteoside on ovariectomy-induced osteoporosis mice. 2022 , 106, 154399	0
63	Effects of bisphosphonates on appendicular fracture repair in rodents. 2022, 164, 116542	1
62	The Effects of Zoledronic Acid Treatment and Endurance Exercise on Ovariectomy-induced Osteopenia in Wistar Rats.	O
61	Incidence of Atypical Femoral Fractures in Patients on Osteoporosis Therapy A Registry-Based Cohort Study.	0
60	Alliance for the development of the Argentinian Hip Fracture Registry. 2022, 17,	O
59	Current use of bone turnover markers in the management of osteoporosis. 2022,	1
58	BNTA alleviates inflammatory osteolysis by the SOD mediated anti-oxidation and anti-inflammation effect on inhibiting osteoclastogenesis. 13,	O
57	Functional and Radiological Outcome in Atypical Subtrochanteric Femur Fracture After Surgical Fixation: A Retrospective Observational Study. 2022 ,	0
56	Three-dimensional morphologic features of Asian atypical femur and clinical implications of cephalomedullary nail fixation: Computational measurement at actual size. 2022 ,	O
55	Osteoporosis and Fragility Fractures: currently available pharmacological options and future directions. 2022 , 101780	2
54	Osteoclast Recycling and the Rebound Phenomenon Following Denosumab Discontinuation.	O
53	Atypical femoral fracture in a bisphosphonate-nalle patient on denosumab for osteoporosis. 2022 , 17,	0
52	Atypical femoral fracture after long-term use of bisphosphonates: case reports and review of the literature. 2021 , 1, 9-13	O
51	Atypical Femoral Fracture (AFF). 2022 , 111-134	0
50	Osteoporosis. 2022 , 179-193	O
49	A mechanistic review of chinese medicine polyphenols on bone formation and resorption. 13,	0
48	Bilateral Subtrochanteric Complete Atypical Femoral Fracture in a Patient With Rheumatoid Arthritis: A Case Report. 2022 ,	O

47	Skeletal Complications. 1-14	0
46	Incomplete Diaphyseal Atypical Femoral Fracture due to Increased Anterolateral Bowing. Publish Ahead of Print,	O
45	Atypical Ulnar Fracture in an Older Woman with Osteoporosis with a Five-Year History of Denosumab Treatment: A Case Report. 2022 , 27, 928-932	О
44	Bone Tumors. 1-27	O
43	Management of Progressive Radioiodine-Refractory Thyroid Carcinoma: Current Perspective. Volume 14, 3047-3062	1
42	Recommendations on the post-acute management of the osteoporotic fracture - Patients with Mery-high Re-fracture risk. 2022 , 37, 94-99	О
41	Finite Element Evaluation of the Femoral Neck System as Prophylactic Fixation to Prevent Contralateral Hip Fractures. 2022 , 13, 215145932211351	О
40	????????????????????????. 2022 , 71, 853-857	O
39	Prevention and treatment of osteoporosis in women. 205336912211399	О
38	Five cases of atypical ulnar fractures associated with long-term bisphosphonate use: An anatomical and mechanical analysis using a finite element model. 2022 ,	О
37	Factors affecting healing and progression of conservatively treated incomplete atypical femoral fractures: retrospective observational study.	O
36	Novel formulations of oral bisphosphonates in the treatment of osteoporosis.	O
35	Anterior radial head dislocation secondary to atypical ulnar fracture with atypical femoral fracture: A case report and literature review. 2022 ,	O
34	Is bisphosphonate use a risk factor for atypical periprosthetic/peri-implant fractures? - A metanalysis of retrospective cohort studies and systematic review of the current evidence. 2022 , 103475	O
33	Effect of Vitamin D 3 Supplementation on Acute Fracture Healing: A Phase II Screening Randomized Double-Blind Controlled Trial.	О
32	Long-term consequences of osteoporosis therapy with denosumab. 2022 , 66, 717-723	O
31	Antiresorptive drugs and the risk of femoral shaft fracture in men and women with osteoporosis: A cohort study using the National Database of Health Insurance Claims of Japan. 2022 ,	0
30	Bone Tumor Mimics. 2021 , 621-659	O

29	Atypical Fractures of the Ulna: Effect of Bowing of the Ulna on Fracture Location and Occurrence. 2022 , 103492	O
28	A low serum alkaline phosphatase may signal hypophosphatasia in osteoporosis clinic patients.	1
27	Etiological analysis and Treatment Principles of Atypical Femur Fracture.	0
26	Atypical femoral fracture mimicking lumbar radiculopathy in two patients taking bisphosphonate long-term: A case report. 2022 , 23,	O
25	Twelve months of denosumab and/or alendronate is associated with improved bone fatigue life, microarchitecture, and density in ovariectomized cynomolgus monkeys.	2
24	Advancement in the Treatment of Osteoporosis and the Effects on Bone Healing. 2022, 11, 7477	O
23	A Quantification Method for Disorganized Bone Components: Application to the Femoral Shaft.	O
22	Imaging of the Acutely Injured Hip. 2022 ,	O
21	Bone Morphogenetic Protein 2 Promotes Bone Formation in Bone Defects in Which Bone Remodeling Is Suppressed by Long-Term and High-Dose Zoledronic Acid. 2023 , 10, 86	O
20	High frequency of heterozygous rare variants of the SLC34A1 and SLC9A3R1 genes in patients with atypical femur fracture.	O
19	A brief review and clinical evidences of teriparatide therapy for atypical femoral fractures associated with long-term bisphosphonate treatment. 9,	O
18	Comparison of Bisphosphonates Versus Teriparatide in Therapy of the Glucocorticoid-Induced Osteoporosis (GIOP): A Meta-Analysis of Randomized Controlled Trials.	O
17	Simultaneous Bilateral Insufficiency Femoral Fractures After Long-Term Alendronate Treatment: A Lesson Not Yet Learned. 2023 ,	O
16	Bilateral Atypical Femoral Fractures after Bisphosphonate Treatment for Osteoporosis: A Literature Review. 2023 , 12, 1038	O
15	Microenvironment-responsive nanocarriers for targeted bone disease therapy. 2023 , 50, 101838	0
14	AAOS Clinical Practice Guideline Summary: Treatment of Metastatic Carcinoma and Myeloma of the Femur. 2023 , 31, e118-e129	O
13	miRNA-27a is essential for bone remodeling by modulating p62-mediated osteoclast signaling. 12,	0
12	Suppression of Remodeling and Bone Fragility. 2023 , 38, 370-371	O

CITATION REPORT

11	Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis. 2023 , 18,	0
10	Weight-Based Bisphosphonate Administration for Multiple Myeloma Patients and the Risks of Skeletal Complications. 2023 , 12, 1637	Ο
9	Iatrogenic Vertebral Fracture During Intramedullary Nailing for Femoral Fracture. 2022, 12,	0
8	Comparison of Fracture Identification Using Different Definitions in Healthcare Administrative (Claims) Data. 2023 , 11, 53	O
7	Atypical Vancouver B1 Periprosthetic Fractures: The Unsolved Problem. 2023 , 14, 215145932211458	0
6	Osteoporosis Prevention and Treatment. 2023 , 587-598	O
5	Outcomes of Angular Stable Locking System in Femoral Diaphyseal Fractures of Elderly Patients: A Multicenter Comparative Study. 15,	O
4	Therapeutic strategy for atypical ulnar fracture in long use of bisphosphonate: A systematic review. 2023 ,	o
3	Risk Factors Associated with Intraoperative latrogenic Fracture in Patients Undergoing Intramedullary Nailing for Atypical Femoral Fractures with Marked Anterior and Lateral Bowing. 2023 , 59, 735	O
2	Multicenter study on atypical femoral fractures in patients with bone metastases taking bone-modifying agents. 2023 , 100478	O
1	Prevalence of Monogenic Bone Disorders in a Dutch Cohort of Atypical Femur Fracture Patients.	О